{"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Hepatotoxicity [see Warnings and Precautions (5.1) ] • Diarrhea [see Warnings and Precautions (5.2) ] • The most common adverse reactions (≥20%) with TUKYSA in combination with trastuzumab and pertuzumab in patients with unresectable locally advanced or metastatic HER2-positive breast cancer are diarrhea, musculoskeletal pain, hepatotoxicity, nausea, fatigue, rash, and vomiting. ( 6.1 ) • The most common adverse reactions (≥20%) with TUKYSA in combination with trastuzumab and capecitabine in patients with metastatic breast cancer are diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash. ( 6.1 ) • The most common adverse reactions (≥20%) with TUKYSA in combination with trastuzumab in patients with unresectable or metastatic colorectal cancer are diarrhea, fatigue, rash, nausea, abdominal pain, infusion related reactions, and pyrexia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Unresectable or Metastatic Breast Cancer Maintenance Treatment of HER2-Positive Metastatic Breast Cancer (HER2CLIMB-05) The safety of TUKYSA in combination with trastuzumab and pertuzumab was evaluated in HER2CLIMB-05 [see Clinical Studies (14.1) ] . Patients received TUKYSA 300 mg twice daily plus trastuzumab and pertuzumab (n = 326) or placebo plus trastuzumab and pertuzumab (n = 324). The median duration of treatment was 17 months (range: 0.4 to 37) for the TUKYSA arm. Serious adverse reactions occurred in 17% of patients who received TUKYSA. Serious adverse reactions in ≥1% of patients included hepatotoxicity (3.9%). One patient experienced a fatal adverse reaction of drug-induced liver injury. Permanent discontinuation of TUKYSA due to an adverse reaction occurred in 14% of patients. Adverse reactions leading to permanent discontinuation in ≥1% of patients were hepatotoxicity (8%) and diarrhea (1.5%). Dosage interruptions of TUKYSA due to an adverse reaction occurred in 49% of patients. Adverse reactions which required dosage interruption in >5% of patients included hepatotoxicity (19%) and diarrhea (9%). Dose reduction of TUKYSA due to an adverse reaction occurred in 29% of patients. Adverse reactions leading to dose reduction in ≥2% of patients were hepatotoxicity (16%) and diarrhea (6%). The most common (≥20%) adverse reactions were diarrhea, musculoskeletal pain, hepatotoxicity, nausea, fatigue, rash, and vomiting. Table 4 summarizes the adverse reactions in HER2CLIMB-05. Table 4: Adverse Reactions (≥10%) in Patients Who Received TUKYSA in HER2CLIMB-05 (All Grades) Adverse Reaction TUKYSA + Trastuzumab + Pertuzumab N = 326 Placebo + Trastuzumab + Pertuzumab N = 324 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Gastrointestinal disorders Diarrhea 73 6 0 51 4 0 Nausea 33 0.9 0 24 0.9 0 Vomiting 20 0.3 0 14 0.3 0 Stomatitis Stomatitis includes angular cheilitis, aphthous ulcer, cheilitis, mouth ulceration, oral dysesthesia, oral pain, oropharyngeal discomfort, oropharyngeal pain, and stomatitis. 18 0 0 18 0 0 Constipation 11 0 0 11 0 0 Musculoskeletal and connective tissue disorders Musculoskeletal pain Musculoskeletal pain includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, musculoskeletal stiffness, myalgia, neck pain, non-cardiac chest pain, pain in extremity, and spinal pain. 45 1.2 0 42 0.9 0 Muscle spasms 14 0 0 12 0.6 0 Hepatobiliary disorders Hepatotoxicity Hepatotoxicity includes ALT increased, AST increased, bilirubin conjugated increased, blood bilirubin increased, drug-induced liver injury, gamma-glutamyltransferase increased, hepatic cytolysis, hepatic failure, hepatotoxicity, hyperbilirubinemia, hypertransaminasemia, liver injury, and transaminases increased. 44 15 2.5 16 1.2 0 General disorders Fatigue Fatigue includes fatigue and asthenia. 33 0.9 0 25 1.9 0 Pyrexia 16 0 0 9 0 0 Skin and subcutaneous tissue disorders Rash Rash includes dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis bullous, erythema, hand dermatitis, rash, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, skin reaction, skin toxicity, and urticaria. 32 0.3 0 27 0.9 0 Pruritus 19 0 0 18 0 0 Nervous system disorders Headache 19 0 0 18 0 0 Respiratory, thoracic and mediastinal disorders Cough 18 0 0 14 0 0 Blood and lymphatic system disorders Anemia 17 1.5 0 9 0.6 0 Infections and infestations Upper respiratory tract infection 16 0 0 8 0.3 0 COVID-19 14 0.3 0 13 0 0 Metabolism and nutrition disorders Decreased appetite 14 0.3 0 7 0.3 0 Investigations Weight decreased 11 0.6 0 9 0.3 0 Other clinically relevant adverse reactions in <10% of patients who received TUKYSA in combination with trastuzumab and pertuzumab included epistaxis (3.7%). Table 5: Laboratory Abnormalities (≥20%) Worsening from Baseline in Patients Who Received TUKYSA and with a Difference of ≥5% Compared to Placebo in HER2CLIMB-05 Laboratory Abnormality TUKYSA + Trastuzumab + Pertuzumab N = 326 Placebo + Trastuzumab + Pertuzumab N = 324 All Grades % Grades ≥3 % All Grades % Grades ≥3 % Chemistry Increased ALT 67 18 32 0.9 Increased AST 60 10 32 0 Increased creatinine 46 0.6 16 0 Increased alkaline phosphatase 29 0 23 0 Decreased potassium 23 3.7 14 0.9 Hematology Decreased leukocytes 27 0.9 21 0.6 Decreased neutrophils 25 2.9 17 1.4 Treatment of HER2-Positive Breast Cancer (HER2CLIMB) The safety of TUKYSA in combination with trastuzumab and capecitabine was evaluated in HER2CLIMB [see Clinical Studies (14.1) ] . Patients received either TUKYSA 300 mg twice daily plus trastuzumab or a non-US approved trastuzumab product, and capecitabine (n = 404) or placebo plus trastuzumab or a non-US approved trastuzumab product and capecitabine (n = 197). The median duration of treatment was 5.8 months (range: 3 days, 2.9 years) for the TUKYSA arm. Serious adverse reactions occurred in 26% of patients who received TUKYSA. Serious adverse reactions in ≥2% of patients who received TUKYSA were diarrhea (4%), vomiting (2.5%), nausea (2%), abdominal pain (2%), and seizure (2%). Fatal adverse reactions occurred in 2% of patients who received TUKYSA including sudden death, sepsis, dehydration, and cardiogenic shock. Adverse reactions leading to treatment discontinuation occurred in 6% of patients who received TUKYSA. Adverse reactions leading to treatment discontinuation of TUKYSA in ≥1% of patients were hepatotoxicity (1.5%) and diarrhea (1%). Adverse reactions leading to dose reduction occurred in 21% of patients who received TUKYSA. Adverse reactions leading to dose reduction of TUKYSA in ≥2% of patients were hepatotoxicity (8%) and diarrhea (6%). The most common adverse reactions in patients who received TUKYSA (≥20%) were diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash. Table 6 summarizes the adverse reactions in HER2CLIMB. Table 6: Adverse Reactions (≥10%) in Patients Who Received TUKYSA and with a Difference Between Arms of ≥5% Compared to Placebo in HER2CLIMB (All Grades) Adverse Reaction TUKYSA + Trastuzumab + Capecitabine N = 404 Placebo + Trastuzumab + Capecitabine N = 197 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Gastrointestinal disorders Diarrhea 81 12 0.5 53 9 0 Nausea 58 3.7 0 44 3 0 Vomiting 36 3 0 25 3.6 0 Stomatitis Stomatitis includes stomatitis, oropharyngeal pain, oropharyngeal discomfort, mouth ulceration, oral pain, lip ulceration, glossodynia, tongue blistering, lip blister, oral dysesthesia, tongue ulceration, and aphthous ulcer. 32 2.5 0 21 0.5 0 Skin and subcutaneous tissue disorders Palmar-plantar erythrodysesthesia syndrome 63 13 0 53 9 0 Rash Rash includes rash maculo-papular, rash, dermatitis acneiform, erythema, rash macular, rash papular, rash pustular, rash pruritic, rash erythematous, skin exfoliation, urticaria, dermatitis allergic, palmar erythema, plantar erythema, skin toxicity, and dermatitis. 20 0.7 0 15 0.5 0 Hepatobiliary disorders Hepatotoxicity Hepatotoxicity includes hyperbilirubinemia, blood bilirubin increased, bilirubin conjugated increased, alanine aminotransferase increased, transaminases increased, hepatotoxicity, aspartate aminotransferase increased, liver function test increased, liver injury, and hepatocellular injury. 42 9 0.2 24 3.6 0 Metabolism and nutrition disorders Decreased appetite 25 0.5 0 20 0 0 Blood and lymphatic system disorders Anemia Anemia includes anemia, hemoglobin decreased, and normocytic anemia. 21 3.7 0 13 2.5 0 Musculoskeletal and connective tissue disorders Arthralgia 15 0.5 0 4.6 0.5 0 Investigations Creatinine increased Due to inhibition of renal tubular transport of creatinine without affecting glomerular function. 14 0 0 1.5 0 0 Weight decreased 13 1 0 6 0.5 0 Nervous System Disorders Peripheral neuropathy Peripheral neuropathy includes peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy. 13 0.5 0 7 1 0 Respiratory, thoracic and mediastinal disorders Epistaxis 12 0 0 5 0 0 Table 7: Laboratory Abnormalities (≥20%) Worsening from Baseline in Patients Who Received TUKYSA and with a Difference of ≥5% Compared to Placebo in HER2CLIMB Laboratory Abnormality TUKYSA + Trastuzumab + Capecitabine The denominator used to calculate the rate varied from 351 to 400 in the TUKYSA arm and 173 to 197 in the control arm based on the number of patients with a baseline value and at least one post-treatment value. Grading was based on NCI CTCAE v.4.03 for laboratory abnormalities, except for increased creatinine which only includes patients with a creatinine increase based on the upper limit of normal definition for Grade 1 events (NCI CTCAE v5.0). Placebo + Trastuzumab + Capecitabine All Grades % Grades ≥3 % All Grades % Grades ≥3 % Hematology Decreased hemoglobin 59 3.3 51 1.5 Chemistry Decreased phosphate 57 8 45 7 Increased bilirubin 47 1.5 30 3.1 Increased ALT 46 8 27 0.5 Increased AST 43 6 25 1 Decreased magnesium 40 0.8 25 0.5 Decreased potassium Laboratory criteria for Grade 1 are identical to laboratory criteria for Grade 2. 36 6 31 5 Increased creatinine 33 0 6 0 Decreased sodium There is no definition for Grade 2 in CTCAE v.4.03. 28 2.5 23 2 Increased alkaline phosphatase 26 0.5 17 0 RAS Wild-Type, HER2-Positive Unresectable or Metastatic Colorectal Cancer The safety of TUKYSA in combination with trastuzumab or a non-US approved trastuzumab product was evaluated in 86 patients enrolled in MOUNTAINEER with unresectable or metastatic colorectal cancer [see Clinical Studies (14.2) ] . The median duration of exposure to TUKYSA was 6.9 months (range 0.7, 49.3). Serious adverse reactions occurred in 22% of patients. Serious adverse reactions that occurred in ≥2% of patients were intestinal obstruction (7%), urinary tract infection (3.5%), pneumonia (2.3%), abdominal pain (2.3%) and rectal perforation (2.3%). Permanent discontinuation of TUKYSA due to an adverse reaction occurred in 6% of patients. The adverse reaction which resulted in permanent discontinuation of TUKYSA in ≥2% of patients was increased ALT (2.3%). Dosage interruptions of TUKYSA due to an adverse reaction occurred in 23% of patients. Adverse reactions which required dosage interruption in ≥3% of patients were increased ALT (3.5%) and diarrhea (3.5%). Dose reductions of TUKYSA due to an adverse reaction occurred in 9% of patients. Adverse reactions which required dose reductions in ≥2% of patients were increased ALT (2.3%) and diarrhea (2.3%). The most common adverse reactions reported in ≥20% of patients treated with TUKYSA and trastuzumab were diarrhea, fatigue, rash, nausea, abdominal pain, infusion related reactions, and pyrexia. The most common laboratory abnormalities reported in ≥20% of patients were increased creatinine, increased glucose, increased ALT, decreased hemoglobin, increased AST, increased bilirubin, increased alkaline phosphatase, decreased lymphocytes, decreased albumin, decreased leukocytes, and decreased sodium. Table 8 summarizes the adverse reactions in MOUNTAINEER. Table 8: Adverse Reactions (≥10%) in Patients with Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER) Adverse Reaction TUKYSA + Trastuzumab N = 86 Includes 1 patient who only received trastuzumab. All Grades % Grade 3 % Gastrointestinal disorders Diarrhea 64 3.5 Nausea 35 0 Vomiting 16 0 Abdominal pain Abdominal pain includes abdominal discomfort, abdominal pain, and abdominal pain upper. 21 2.3 Constipation 14 1.2 General disorders Fatigue 44 2.3 Pyrexia 20 0 Chills 19 1.2 Skin and subcutaneous disorders Rash Rash includes acne, dermatitis acneiform, dermatitis contact, erythema, erythema multiforme, rash, rash macular, rash maculo-papular, rash papular, rash pustular, skin exfoliation, and urticaria. 37 0 Injury, poisoning, and procedural complications Infusion related reaction 21 0 Metabolism and nutrition disorders Decreased appetite 19 0 Blood and lymphatic system disorders Anemia 10 0 Vascular disorders Hypertension 17 7 Musculoskeletal and connective tissue disorders Back pain 17 2.3 Arthralgia 16 1.2 Myalgia 13 0 Respiratory, thoracic and mediastinal disorders Cough 16 0 Dyspnea 14 0 Psychiatric disorders Anxiety 10 0 Other clinically relevant adverse reactions in <10% of patients who received TUKYSA in combination with trastuzumab include epistaxis (7%), weight decreased (7%), oropharyngeal pain (5%), oral dysesthesia (1%), and stomatitis (1%). Table 9: Laboratory Abnormalities (≥15%) Worsening from Baseline in Patients with Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER) Laboratory Abnormality TUKYSA + Trastuzumab N = 85 Number of patients with both baseline and post-baseline results for each test. All Grades % Grade 3 % Grade 4 % Hematology Decreased hemoglobin 46 3.5 0 Decreased lymphocytes 39 12 0 Decreased leukocytes 22 0 0 Decreased platelets 15 0 0 Chemistry Increased creatinine NCI CTCAE v5.0 was used for creatinine increased. NCI CTCAE v4.03 was used for all other laboratory parameters. 58 0 0 Increased glucose 56 2.4 0 Increased ALT 46 2.4 2.4 Increased AST 33 2.4 3.5 Increased bilirubin 28 3.5 2.4 Increased alkaline phosphatase 25 1.2 0 Decreased albumin 24 1.2 0 Decreased sodium 20 6 0 Decreased potassium 16 1.2 0"],"adverse_reactions_table":["<table styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 4: Adverse Reactions (&#x2265;10%) in Patients Who Received TUKYSA in HER2CLIMB-05 (All Grades)</caption> <col width=\"28%\"/> <col width=\"12%\"/> <col width=\"12%\"/> <col width=\"12%\"/> <col width=\"12%\"/> <col width=\"12%\"/> <col width=\"12%\"/> <tbody> <tr> <td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Adverse Reaction</content> </paragraph> </td> <td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">TUKYSA + Trastuzumab + Pertuzumab</content> </paragraph> <paragraph> <content styleCode=\"bold\">N = 326</content> </paragraph> </td> <td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Placebo + Trastuzumab + Pertuzumab</content> </paragraph> <paragraph> <content styleCode=\"bold\">N = 324</content> </paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">All Grades</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Grade 3</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Grade 4</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">All Grades</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Grade 3</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Grade 4</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Gastrointestinal disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Diarrhea</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>73</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>51</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>4</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Nausea</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>33</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>24</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Vomiting </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>20</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>14</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Stomatitis<footnote ID=\"_Ref242282840\">Stomatitis includes angular cheilitis, aphthous ulcer, cheilitis, mouth ulceration, oral dysesthesia, oral pain, oropharyngeal discomfort, oropharyngeal pain, and stomatitis.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>18</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>18</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Constipation</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>11</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>11</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Musculoskeletal pain<footnote ID=\"_Ref242282877\">Musculoskeletal pain includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, musculoskeletal stiffness, myalgia, neck pain, non-cardiac chest pain, pain in extremity, and spinal pain.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>45</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.2</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>42</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Muscle spasms</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>14</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>12</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Hepatobiliary disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Hepatotoxicity<footnote ID=\"_Ref242282883\">Hepatotoxicity includes ALT increased, AST increased, bilirubin conjugated increased, blood bilirubin increased, drug-induced liver injury, gamma-glutamyltransferase increased, hepatic cytolysis, hepatic failure, hepatotoxicity, hyperbilirubinemia, hypertransaminasemia, liver injury, and transaminases increased.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>44</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>15</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>16</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.2</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">General disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Fatigue<footnote ID=\"_Ref242282917\">Fatigue includes fatigue and asthenia.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>33</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>25</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Pyrexia</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>16</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Rash<footnote ID=\"_Ref242282925\">Rash includes dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis bullous, erythema, hand dermatitis, rash, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, skin reaction, skin toxicity, and urticaria.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>32</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>27</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Pruritus</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>19</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>18</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Nervous system disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Headache</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>19</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>18</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Respiratory, thoracic and mediastinal disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Cough</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>18</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>14</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Blood and lymphatic system disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Anemia</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>17</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Infections and infestations</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Upper respiratory tract infection</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>16</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>8</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>COVID-19</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>14</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>13</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Metabolism and nutrition disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased appetite</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>14</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>7</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Investigations</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Weight decreased</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>11</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0.6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0.3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> </tbody> </table>","<table styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 5: Laboratory Abnormalities (&#x2265;20%) Worsening from Baseline in Patients Who Received TUKYSA and with a Difference of &#x2265;5% Compared to Placebo in HER2CLIMB-05</caption> <col width=\"34%\"/> <col width=\"17%\"/> <col width=\"17%\"/> <col width=\"17%\"/> <col width=\"17%\"/> <tbody> <tr> <td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Laboratory Abnormality</content> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">TUKYSA + Trastuzumab + Pertuzumab</content> </paragraph> <paragraph> <content styleCode=\"bold\">N = 326</content> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Placebo + Trastuzumab + Pertuzumab</content> </paragraph> <paragraph> <content styleCode=\"bold\">N = 324</content> </paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">All Grades</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Grades &#x2265;3</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">All Grades</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Grades &#x2265;3</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> </tr> <tr> <td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Chemistry</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased ALT </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>67</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>18</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>32</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.9</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased AST </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>60</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>10</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>32</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased creatinine</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>46</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>16</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased alkaline phosphatase</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>29</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>23</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased potassium</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>23</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.7</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>14</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.9</paragraph> </td> </tr> <tr> <td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Hematology</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased leukocytes</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>27</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>21</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.6</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Decreased neutrophils</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>25</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>2.9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>17</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>1.4</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefSPLSERV-8ab90929-cf1e-494a-a3ed-c4ce\" width=\"100%\"> <caption>Table 6: Adverse Reactions (&#x2265;10%) in Patients Who Received TUKYSA and with a Difference Between Arms of &#x2265;5% Compared to Placebo in HER2CLIMB (All Grades)</caption> <col width=\"29%\"/> <col width=\"12%\"/> <col width=\"12%\"/> <col width=\"12%\"/> <col width=\"12%\"/> <col width=\"11%\"/> <col width=\"11%\"/> <tbody> <tr> <td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Adverse Reaction</content> </paragraph> </td> <td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">TUKYSA + Trastuzumab + Capecitabine</content> </paragraph> <paragraph> <content styleCode=\"bold\">N = 404</content> </paragraph> </td> <td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Placebo + Trastuzumab + Capecitabine</content> </paragraph> <paragraph> <content styleCode=\"bold\">N = 197</content> </paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">All Grades</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Grade 3</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Grade 4</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">All Grades</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Grade 3</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Grade 4</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Gastrointestinal disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Diarrhea</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>81</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>12</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>53</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Nausea</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>58</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.7</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>44</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Vomiting </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>36</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>25</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Stomatitis<footnote ID=\"_Ref171610035\">Stomatitis includes stomatitis, oropharyngeal pain, oropharyngeal discomfort, mouth ulceration, oral pain, lip ulceration, glossodynia, tongue blistering, lip blister, oral dysesthesia, tongue ulceration, and aphthous ulcer.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>32</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>21</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Palmar-plantar erythrodysesthesia syndrome</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>63</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>13</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>53</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Rash<footnote ID=\"_Ref171610055\">Rash includes rash maculo-papular, rash, dermatitis acneiform, erythema, rash macular, rash papular, rash pustular, rash pruritic, rash erythematous, skin exfoliation, urticaria, dermatitis allergic, palmar erythema, plantar erythema, skin toxicity, and dermatitis.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>20</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.7</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>15</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Hepatobiliary disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Hepatotoxicity<footnote ID=\"_Ref171610064\">Hepatotoxicity includes hyperbilirubinemia, blood bilirubin increased, bilirubin conjugated increased, alanine aminotransferase increased, transaminases increased, hepatotoxicity, aspartate aminotransferase increased, liver function test increased, liver injury, and hepatocellular injury.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>42</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>9</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.2</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>24</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Metabolism and nutrition disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased appetite</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>25</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>20</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Blood and lymphatic system disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Anemia<footnote ID=\"_Ref171610073\">Anemia includes anemia, hemoglobin decreased, and normocytic anemia.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>21</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.7</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>13</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Arthralgia</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>15</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>4.6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Investigations</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Creatinine increased<footnote ID=\"_Ref171610081\">Due to inhibition of renal tubular transport of creatinine without affecting glomerular function.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>14</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Weight decreased</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>13</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Nervous System Disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Peripheral neuropathy<footnote ID=\"_Ref171610088\">Peripheral neuropathy includes peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>13</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>7</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"7\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Respiratory, thoracic and mediastinal disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Epistaxis</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>12</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefID0EJVAG\" styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 7: Laboratory Abnormalities (&#x2265;20%) Worsening from Baseline in Patients Who Received TUKYSA and with a Difference of &#x2265;5% Compared to Placebo in HER2CLIMB</caption> <col width=\"34%\"/> <col width=\"17%\"/> <col width=\"17%\"/> <col width=\"17%\"/> <col width=\"17%\"/> <tbody> <tr> <td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Laboratory Abnormality</content> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">TUKYSA + Trastuzumab + Capecitabine</content> <footnote ID=\"_Ref171610144\">The denominator used to calculate the rate varied from 351 to 400 in the TUKYSA arm and 173 to 197 in the control arm based on the number of patients with a baseline value and at least one post-treatment value. Grading was based on NCI CTCAE v.4.03 for laboratory abnormalities, except for increased creatinine which only includes patients with a creatinine increase based on the upper limit of normal definition for Grade 1 events (NCI CTCAE v5.0).</footnote> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Placebo + Trastuzumab + Capecitabine</content> <footnoteRef IDREF=\"_Ref171610144\"/> </paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">All Grades</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Grades &#x2265;3</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">All Grades</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Grades &#x2265;3</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> </tr> <tr> <td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Hematology</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased hemoglobin</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>59</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.3</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>51</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.5</paragraph> </td> </tr> <tr> <td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Chemistry</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased phosphate</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>57</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>8</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>45</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>7</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased bilirubin</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>47</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>30</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.1</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased ALT</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>46</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>8</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>27</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased AST</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>43</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>25</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased magnesium</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>40</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.8</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>25</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased potassium<footnote ID=\"_Ref171610162\">Laboratory criteria for Grade 1 are identical to laboratory criteria for Grade 2.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>36</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>31</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>5</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased creatinine</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>33</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased sodium<footnote ID=\"_Ref171610174\">There is no definition for Grade 2 in CTCAE v.4.03.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>28</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>23</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Increased alkaline phosphatase</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>26</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>17</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefID0EOABG\" styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 8: Adverse Reactions (&#x2265;10%) in Patients with Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER)</caption> <col width=\"31%\"/> <col width=\"36%\"/> <col width=\"33%\"/> <tbody> <tr> <td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Adverse Reaction</content> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">TUKYSA + Trastuzumab</content> </paragraph> <paragraph> <content styleCode=\"bold\">N = 86</content> <footnote ID=\"_Ref171610278\">Includes 1 patient who only received trastuzumab.</footnote> </paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">All Grades</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Grade 3</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Gastrointestinal disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Diarrhea</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>64</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.5</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Nausea</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>35</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Vomiting</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>16</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Abdominal pain<footnote ID=\"_Ref171610269\">Abdominal pain includes abdominal discomfort, abdominal pain, and abdominal pain upper.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>21</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.3</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Constipation</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>14</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.2</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">General disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Fatigue</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>44</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.3</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Pyrexia</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>20</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Chills</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>19</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.2</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Skin and subcutaneous disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Rash<footnote ID=\"_Ref171610286\">Rash includes acne, dermatitis acneiform, dermatitis contact, erythema, erythema multiforme, rash, rash macular, rash maculo-papular, rash papular, rash pustular, skin exfoliation, and urticaria.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>37</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Injury, poisoning, and procedural complications</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Infusion related reaction</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>21</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Metabolism and nutrition disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased appetite</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>19</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Blood and lymphatic system disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Anemia</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>10</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Vascular disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Hypertension</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>17</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>7</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Back pain</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>17</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.3</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Arthralgia</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>16</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.2</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Myalgia</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>13</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Respiratory, thoracic and mediastinal disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Cough</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>16</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Dyspnea</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>14</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Psychiatric disorders</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Anxiety</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>10</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefSPLSERV-55a2105d-c50f-4b4c-a407-01af\" styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 9: Laboratory Abnormalities (&#x2265;15%) Worsening from Baseline in Patients with Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER)</caption> <col width=\"31%\"/> <col width=\"19%\"/> <col width=\"25%\"/> <col width=\"25%\"/> <tbody> <tr> <td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Laboratory Abnormality</content> </paragraph> </td> <td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">TUKYSA + Trastuzumab</content> </paragraph> <paragraph> <content styleCode=\"bold\">N = 85</content> <footnote ID=\"_Ref171610340\">Number of patients with both baseline and post-baseline results for each test.</footnote> </paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">All Grades</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Grade 3</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Grade 4</content> </paragraph> <paragraph> <content styleCode=\"bold\">%</content> </paragraph> </td> </tr> <tr> <td colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Hematology</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased hemoglobin</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>46</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased lymphocytes</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>39</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>12</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased leukocytes</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>22</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased platelets</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>15</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Chemistry</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased creatinine<footnote ID=\"_Ref171610349\">NCI CTCAE v5.0 was used for creatinine increased. NCI CTCAE v4.03 was used for all other laboratory parameters.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>58</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased glucose</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>56</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.4</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased ALT</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>46</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>2.4</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>2.4</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased AST</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>33</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>2.4</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>3.5</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased bilirubin</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>28</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.5</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.4</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Increased alkaline phosphatase</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>25</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.2</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased albumin</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>24</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.2</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Decreased sodium</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>20</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>6</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Decreased potassium</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>16</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>1.2</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>0</paragraph> </td> </tr> </tbody> </table>"],"boxed_warning":["WARNING: HEPATOTOXICITY • TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge [see Warnings and Precautions (5.1) ] . • Obtain liver function tests before initiation and during treatment with TUKYSA. Withhold, reduce dose, or permanently discontinue TUKYSA as recommended based on severity of hepatotoxicity [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. • TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge. ( 5.1 ) • Obtain liver function tests before initiation and during treatment with TUKYSA. Withhold, reduce dose, or permanently discontinue based on severity. ( 2.3 , 5.1 )"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with tucatinib. Tucatinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay. Tucatinib was not clastogenic in either an in vitro chromosome aberration assay or an in vivo mouse bone marrow micronucleus assay. Fertility studies in animals have not been conducted. In repeat-dose toxicity studies up to 13 weeks duration, decreased corpora lutea/corpus luteum cyst, increased interstitial cells of the ovary, atrophy of the uterus, and mucification of the vagina were observed in female rats at doses ≥6 mg/kg/day (approximately 0.1 times the human exposure at the recommended dose based on AUC). Atrophy and edema of the testes and oligospermia/germ cell debris in the epididymides were observed in male rats at ≥120 mg/kg/day (approximately 13 times the human exposure at the recommended dose based on AUC)."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro , tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo , tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone. 12.2 Pharmacodynamics Exposure-Response Relationship Tucatinib exposure-response relationships and the time course of pharmacodynamics response have not been fully characterized. Cardiac Electrophysiology No large mean increase in QTc (i.e., >20 ms) was detected following treatment with TUKYSA at the recommended dose of 300 mg taken orally twice daily. 12.3 Pharmacokinetics Tucatinib AUC 0-INF and C max increased proportionally over a dosage range from 50 mg to 300 mg (0.17 to 1 times the approved recommended dosage). Time to steady state was approximately 4 days. Steady-state pharmacokinetic parameters following administration of TUKYSA 300 mg twice daily for 7 days in patients with mBC and mCRC are described in Table 12. The geometric mean (CV%) tucatinib AUC accumulation ratios ranged from 2.0 (26) fold to 2.5 (28) fold. Table 12: Tucatinib C max and AUC Tumor Type AUC ss (ng*h/mL) C max,ss (ng/mL) C trough,ss (ng/mL) mBC 5620 (43) 747 (45) 288 (59) mCRC 3370 (49) 405 (45) 197 (63) Absorption The median time to peak plasma concentration of tucatinib was approximately 2 hours (range 1 to 4 hours). Effects of Food Following administration of a single oral dose of TUKYSA in 11 subjects after a high-fat meal (approximately 58% fat, 26% carbohydrate, and 16% protein), the mean AUC 0-INF increased by 1.5-fold, the T max shifted from 1.5 hours to 4 hours, and C max was unaltered. The effect of food on the pharmacokinetics of tucatinib was not clinically meaningful. Distribution The geometric mean (CV%) apparent volume of distribution of tucatinib at steady-state were 903 (42) L and 829 (21) L in patients with mBC and mCRC, respectively. The plasma protein binding was 97.1% at clinically relevant concentrations. At steady-state, concentrations of tucatinib and its metabolite ONT-993 in the cerebrospinal fluid were comparable to unbound plasma concentrations. Elimination At steady-state, tucatinib effective half-life was approximately 11.9 hours and geometric mean (CV%) apparent clearance was 53 (43) L/h in patients with mBC. Tucatinib effective half-life was approximately 16.4 hours and geometric mean (CV%) apparent clearance was 89 (49) L/h in patients with mCRC. Metabolism Tucatinib is metabolized primarily by CYP2C8 and to a lesser extent via CYP3A. Excretion Following a single oral dose of 300 mg radiolabeled tucatinib, approximately 86% of the total radiolabeled dose was recovered in feces (16% of the administered dose as unchanged tucatinib) and 4.1% in urine with an overall total recovery of 90% within 13 days post-dose. In plasma, approximately 76% of the plasma radioactivity was unchanged, 19% was attributed to identified metabolites, and approximately 5% was unassigned. Specific Populations Age (18-77 years), albumin (19 to 52 g/L), creatinine clearance (CLcr: 60 to 89 mL/min (n = 63); CLcr 30 to 59 mL/min (n = 6)), body weight (41 to 146 kg), sex (male (n = 170), female (n = 113)) and race (White (n = 205), Black (n = 37), or Asian (n = 25)) did not have a clinically meaningful effect on tucatinib exposure. Renal Impairment No clinically significant differences in the pharmacokinetics of tucatinib were observed in patients with mild to moderate renal impairment (CLcr: 30 to 89 mL/min by Cockcroft-Gault). The effect of severe renal impairment (CLcr: <30 mL/min) on the pharmacokinetics of tucatinib is unknown. Hepatic Impairment Mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment had no clinically relevant effect on tucatinib exposure. Tucatinib AUC 0-INF was increased by 1.6 fold in subjects with severe (Child-Pugh C) hepatic impairment compared to subjects with normal hepatic function. Drug Interaction Studies Clinical Studies Table 13: Effect of Other Drugs on TUKYSA Concomitant Drug (Dose) TUKYSA Dose Ratio (90% CI) of Tucatinib Exposure With and Without Concomitant Drug C max AUC Strong CYP3A Inhibitor Itraconazole (200 mg BID) 300 mg single dose 1.3 (1.2, 1.4) 1.3 (1.3, 1.4) Strong CYP3A/Moderate 2C8 Inducer Rifampin (600 mg once daily) 0.6 (0.5, 0.8) 0.5 (0.4, 0.6) Strong CYP2C8 Inhibitor Gemfibrozil (600 mg BID) 1.6 (1.5, 1.8) 3.0 (2.7, 3.5) Table 14: Effect of TUKYSA on Other Drugs Concomitant Drug (Dose) TUKYSA Dose Ratio (90% CI) of Exposure Measures of Concomitant Drug with/without Tucatinib C max AUC CYP2C8 Substrate Repaglinide (0.5 mg single dose) 300 mg twice daily 1.7 (1.4, 2.1) 1.7 (1.5, 1.9) CYP3A Substrate Midazolam (2 mg single dose) 3.0 (2.6, 3.4) 5.7 (5.0, 6.5) P-gp Substrate Digoxin (0.5 mg single dose) 2.4 (1.9, 2.9) 1.5 (1.3, 1.7) MATE1/2-K substrate Tucatinib reduced the renal clearance of metformin without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C. Metformin (850 mg single dose) 1.1 (1.0, 1.2) 1.4 (1.2, 1.5) No clinically significant difference in the pharmacokinetics of tucatinib were observed when used concomitantly with omeprazole (proton pump inhibitor) or tolbutamide (sensitive CYP2C9 substrate). In Vitro Studies Cytochrome P450 (CYP) Enzymes: Tucatinib is a reversible inhibitor of CYP2C8 and CYP3A and a time-dependent inhibitor of CYP3A, but is not an inhibitor of CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6. Uridine diphosphate (UDP)-glucuronosyl transferase (UGT) Enzymes: Tucatinib is not an inhibitor of UGT1A1. Transporter Systems: Tucatinib is a substrate of P-gp and BCRP, but is not a substrate of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, or BSEP. Tucatinib inhibits MATE1/MATE2-K-mediated transport of metformin and OCT2/MATE1-mediated transport of creatinine. The observed serum creatinine increase in clinical studies with tucatinib is due to inhibition of tubular secretion of creatinine via OCT2 and MATE1."],"clinical_pharmacology_table":["<table ID=\"_RefID0ERGAI\" styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 12: Tucatinib C<sub>max</sub> and AUC</caption> <col width=\"25%\"/> <col width=\"25%\"/> <col width=\"25%\"/> <col width=\"25%\"/> <tbody> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Tumor Type</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">AUC<sub>ss </sub>(ng*h/mL)</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">C<sub>max,ss </sub>(ng/mL)</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">C<sub>trough,ss </sub>(ng/mL)</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>mBC</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>5620 (43)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>747 (45)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>288 (59)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>mCRC</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>3370 (49)</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>405 (45)</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>197 (63)</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefID0EOKAI\" styleCode=\"Noautorules\" width=\"90%\"> <caption>Table 13: Effect of Other Drugs on TUKYSA</caption> <col width=\"36%\"/> <col width=\"20%\"/> <col width=\"22%\"/> <col width=\"22%\"/> <tbody> <tr> <td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Concomitant Drug</content>   <content styleCode=\"bold\">(Dose)</content> </paragraph> </td> <td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">TUKYSA Dose</content> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Ratio (90% CI) of Tucatinib</content>   <content styleCode=\"bold\">Exposure With and Without</content>   <content styleCode=\"bold\">Concomitant Drug</content> </paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">C<sub>max</sub> </content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">AUC</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">Strong CYP3A Inhibitor</content>  Itraconazole (200 mg BID)</paragraph> </td> <td align=\"center\" rowspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>300 mg single dose</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.3 (1.2, 1.4)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.3 (1.3, 1.4)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">Strong CYP3A/Moderate 2C8 Inducer</content>  Rifampin (600 mg once daily)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.6 (0.5, 0.8)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5 (0.4, 0.6)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">Strong CYP2C8 Inhibitor</content>  Gemfibrozil (600 mg BID)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>1.6 (1.5, 1.8)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>3.0 (2.7, 3.5)</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefID0EEOAI\" styleCode=\"Noautorules\" width=\"90%\"> <caption>Table 14: Effect of TUKYSA on Other Drugs</caption> <col width=\"35%\"/> <col width=\"22%\"/> <col width=\"22%\"/> <col width=\"22%\"/> <tbody> <tr> <td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Concomitant Drug</content>   <content styleCode=\"bold\">(Dose)</content> </paragraph> </td> <td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">TUKYSA Dose</content> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Ratio (90% CI) of Exposure</content>   <content styleCode=\"bold\">Measures of Concomitant Drug</content>   <content styleCode=\"bold\">with/without Tucatinib</content> </paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">C<sub>max</sub> </content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">AUC</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">CYP2C8 Substrate</content>  Repaglinide (0.5 mg single dose)</paragraph> </td> <td align=\"center\" rowspan=\"4\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>300 mg twice daily</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.7 (1.4, 2.1)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.7 (1.5, 1.9)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">CYP3A Substrate</content>  Midazolam (2 mg single dose)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.0 (2.6, 3.4)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>5.7 (5.0, 6.5)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">P-gp Substrate  </content>Digoxin (0.5 mg single dose)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.4 (1.9, 2.9)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.5 (1.3, 1.7)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">MATE1/2-K substrate</content> <footnote ID=\"_Ref171610446\">Tucatinib reduced the renal clearance of metformin without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C.</footnote>  Metformin (850 mg single dose)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>1.1 (1.0, 1.2)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>1.4 (1.2, 1.5)</paragraph> </td> </tr> </tbody> </table>"],"clinical_studies":["14 CLINICAL STUDIES 14.1 Unresectable or Metastatic Breast Cancer Maintenance Treatment of HER2-Positive Breast Cancer HER2CLIMB-05 The efficacy of TUKYSA in combination with trastuzumab and pertuzumab was evaluated in 654 adult patients in HER2CLIMB-05 (NCT05132582), a randomized (1:1), double-blind, placebo-controlled trial. Eligible patients were required to have HER2-positive, unresectable locally advanced or metastatic breast cancer, with or without brain metastases, and no evidence of disease progression by investigator assessment (i.e., experiencing a complete response, partial response, or stable disease) after induction treatment with 4-8 cycles of trastuzumab, pertuzumab, and a taxane. Tumor HER2 positivity was determined at a central laboratory by immunohistochemistry (IHC) and in situ hybridization (ISH) prior to randomization (defined as a 3+ score on IHC and/or 2+ IHC and concurrent positive by ISH). Patients with a presence or history of brain metastases were eligible provided they were asymptomatic and stable and did not require immediate local treatment. Randomization was stratified by the presence or history of brain metastases (yes vs. no), hormone receptor status (positive vs. negative), and diagnosis ( de novo vs. recurrent). Patients received TUKYSA 300 mg or placebo orally twice daily with trastuzumab 6 mg/kg intravenously or subcutaneously at a fixed dose of 600 mg and pertuzumab 420 mg intravenously once every 21 days, or with a fixed-dose combination of 600 mg trastuzumab, 600 mg pertuzumab, and 20,000 units hyaluronidase given subcutaneously every 21 days. Patients with hormone receptor positive disease were permitted to continue endocrine therapy (with ovarian suppression, if applicable). Patients were treated until disease progression or unacceptable toxicity. The primary efficacy outcome measure was progression-free survival (PFS) by investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Additional efficacy outcome measures included overall survival (OS). The median age was 54 years (range: 24 - 83); 108 (17%) patients were 65 years of age and older. Forty-five percent were White, 35% were Asian, and 3% were Black; 19% were Hispanic or Latino and 66% were not Hispanic or Latino, and 14% were missing/unknown; all were female; and patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (64%), 1 (36%), or 2 (0.3%). Fifty-three percent had estrogen and/or progesterone receptor-positive disease. Twelve percent had a presence or history of brain metastases and 56% of patients had visceral metastases. Efficacy results are summarized in Table 15 and Figure 1. Overall survival data were not mature at the time of PFS analysis, with 51 deaths (8%) across both arms in the overall population. Table 15: Efficacy Results in HER2CLIMB-05 Abbreviations: CI = confidence interval; NR = not reached; PFS = progression-free survival. TUKYSA + Trastuzumab + Pertuzumab (N = 326) Placebo + Trastuzumab + Pertuzumab (N = 328) PFS per Investigator Number of events (%) 141 (43) 191 (58) Median, months (95% CI) 24.9 (21.3, NR) 16.3 (12.6, 18.7) Hazard ratio (95% CI) Computed using stratification factors: presence or history of brain metastases (yes vs. no), hormone receptor status (positive vs. negative), and diagnosis ( de novo vs. recurrent). Hazard ratio is calculated based on a stratified Cox proportional hazards model. 0.64 (0.51, 0.80) P-value Two-sided P-value is calculated using the stratified log-rank test. <0.0001 Figure 1: Kaplan-Meier Plot of PFS per Investigator in HER2CLIMB-05 Treatment of HER2-Positive Breast Cancer HER2CLIMB The efficacy of TUKYSA in combination with trastuzumab and capecitabine was evaluated in 612 patients in HER2CLIMB (NCT02614794), a randomized (2:1), double-blind, placebo-controlled trial. Patients were required to have HER2-positive, unresectable locally advanced or metastatic breast cancer, with or without brain metastases, and prior treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) separately or in combination, in the neoadjuvant, adjuvant or metastatic setting. HER2 positivity was based on archival or fresh tissue tested with an FDA-approved test at a central laboratory prior to enrollment with HER2 positivity defined as HER2 IHC 3+ or ISH positive. Patients with brain metastases, including those with progressing or untreated lesions, were eligible provided they were neurologically stable and did not require immediate radiation or surgery. The trial excluded patients with leptomeningeal disease. Randomization was stratified by the presence or history of brain metastases (yes vs. no), ECOG performance status (0 vs. 1), and region (U.S., Canada, or rest of world). Patients received TUKYSA 300 mg or placebo orally twice daily with a trastuzumab or a non-U.S. approved trastuzumab product loading dose of 8 mg/kg on Day 1 of Cycle 1 if needed and then a maintenance dose of 6 mg/kg on Day 1 of every 21-day cycle thereafter and capecitabine 1000 mg/m 2 orally twice daily on Days 1 through 14 of every 21-day cycle. An alternate trastuzumab dosing regimen was 600 mg administered subcutaneously on Day 1 of every 21-day cycle. Patients were treated until disease progression or unacceptable toxicity. Tumor assessments, including brain-MRI in patients with presence or history of brain metastases at baseline, occurred every 6 weeks for the first 24 weeks and every 9 weeks thereafter. The major efficacy outcome measure was PFS in the first 480 randomized patients assessed by Blinded Independent Central Review (BICR) using RECIST v1.1. Additional efficacy outcome measures were evaluated in all randomized patients and included OS, PFS among patients with a history or presence of brain metastases (PFS BrainMets ) and confirmed objective response rate (ORR). The median age was 54 years (range: 22 - 82); 116 (19%) patients were age 65 or older. The majority were White (73%) and female (99%) and 51% had an ECOG performance status of 1. Sixty percent had estrogen and/or progesterone receptor-positive disease. Forty-eight percent had a presence or history of brain metastases; of these patients, 23% had untreated brain metastases, 40% had treated but stable brain metastases, and 37% had treated but radiographically progressing brain metastases. Seventy-four percent of patients had visceral metastases. Patients had received a median of 4 (range, 2 to 17) prior lines of systemic therapy and a median of 3 (range, 1 to 14) prior lines of systemic therapy in the metastatic setting. All patients received prior trastuzumab and T-DM1 and all but 2 patients had prior pertuzumab. Efficacy results are summarized in Table 16 and Figures 2 and 3. Efficacy results were consistent across patient subgroups defined by stratification factors (presence or history of brain metastases, ECOG status, region of world) and hormone receptor status. Table 16: Efficacy Results in HER2CLIMB Abbreviations: BICR = blinded independent central review; CI = confidence interval; CR = complete response; DOR = duration of response; OS = overall survival; ORR = objective response rate; PFS = progression-free survival; PR = partial response. TUKYSA + Trastuzumab + Capecitabine Placebo + Trastuzumab + Capecitabine PFS Primary PFS analysis conducted in first 480 randomized patients. N = 320 N = 160 Number of events (%) 178 (56) 97 (61) Median, months (95% CI) 7.8 (7.5, 9.6) 5.6 (4.2, 7.1) Hazard ratio (95% CI) Hazard ratio and 95% confidence intervals are based on stratified Cox proportional hazards regression model controlling for stratification factors (presence or history of brain metastases, ECOG status, and region of world). 0.54 (0.42, 0.71) P-value Two-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.05. <0.00001 OS N = 410 N = 202 Number of deaths (%) 130 (32) 85 (42) Median, months (95% CI) 21.9 (18.3, 31.0) 17.4 (13.6, 19.9) Hazard ratio (95% CI) 0.66 (0.50, 0.87) P-value Two-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.0074 for this interim analysis (with 60% of the planned number of events for final analysis). 0.00480 PFS BrainMets Analysis includes patients with history or presence of parenchymal brain metastases at baseline, including target and non-target lesions. Does not include patients with dural lesions only. N = 198 N = 93 Number of events (%) 106 (53.5) 51 (54.8) Median, months (95% CI) 7.6 (6.2, 9.5) 5.4 (4.1, 5.7) Hazard ratio (95% CI) 0.48 (0.34, 0.69) P-value Two-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.0080 for this interim analysis (with 71% of the planned number of events for final analysis). <0.00001 Confirmed ORR for Patients with Measurable Disease N = 340 N = 171 ORR (95% CI) Two-sided 95% exact confidence interval, computed using the Clopper-Pearson method (1934). 40.6 (35.3, 46.0) 22.8 (16.7, 29.8) CR (%) 3 (0.9) 2 (1.2) PR (%) 135 (39.7) 37 (21.6) P-value 0.00008 DOR Median, months (95% CI) Calculated using the complementary log-log transformation method (Collett, 1994). 8.3 (6.2, 9.7) 6.3 (5.8, 8.9) Figure 2: Kaplan-Meier Plot of PFS per BICR in HER2CLIMB Figure 3: Kaplan-Meier Plot of Overall Survival in HER2CLIMB Figure 1 Figure 2 Figure 3 14.2 HER2-Positive Metastatic Colorectal Cancer The efficacy of TUKYSA in combination with trastuzumab was evaluated in 84 patients in MOUNTAINEER (NCT03043313), an open-label, multicenter trial. Patients were required to have HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer and prior treatment with fluoropyrimidines, oxaliplatin, irinotecan, and anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb). Patients whose disease had deficient mismatch repair (dMMR) proteins or microsatellite instability-high (MSI-H) must have also received an anti-programmed cell death protein-1 (PD-1) mAb. Patients who received prior anti-HER2 targeting therapy were excluded. HER2 positivity as defined by HER2 overexpression or gene amplification was prospectively determined in local laboratories using immunohistochemistry (IHC), in situ hybridization (ISH), and/or next generation sequencing (NGS) on tumor tissue. RAS status was performed as standard of care prior to study entry based on expanded RAS testing including KRAS exons 2, 3, and 4 and NRAS exons 2, 3, and 4. The median age was 55 years (range: 24 to 77); 12 (14%) patients were age 65 or older. Seventy-seven percent of patients were White, 4% were Black, 4% were Asian, and 4% were Hispanic or Latino. Sixty-one percent of patients were male. Seventy percent of patients had lung metastases, 64% had liver metastases, 60% had an ECOG performance status of 0, 37% had an ECOG performance status of 1, and 4% had an ECOG performance status of 2. Ninety-nine percent of patients received prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan and 83% and 52% received anti-VEGF antibodies and anti-EGFR antibodies respectively; 23%, 38%, and 39% received 1, 2, or ≥3 prior lines of therapy, respectively. Patients received TUKYSA 300 mg orally twice per day with a loading dose of trastuzumab or a non-U.S. approved trastuzumab product 8 mg/kg intravenously on Day 1 of Cycle 1, followed by a maintenance dose of trastuzumab 6 mg/kg on Day 1 of each subsequent 21-day cycle. Patients were treated until disease progression or unacceptable toxicity. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR) as assessed by BICR according to RECIST version 1.1. Efficacy results are summarized in Table 17. Table 17: Efficacy Results in MOUNTAINEER TUKYSA + trastuzumab N = 84 Overall Response Rate (%) (95% CI) 38 (28, 49) CR (%) 3 (3.6) PR (%) 29 (35) Duration of Response N = 32 Median Based on Kaplan-Meier method. , months (95% CI) 12.4 (8.5, 20.5) Patients with DOR≥6 months Based on observed duration of response. 81% Patients with DOR≥12 months 34%"],"clinical_studies_table":["<table styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 15: Efficacy Results in HER2CLIMB-05</caption> <col width=\"34%\"/> <col width=\"34%\"/> <col width=\"32%\"/> <tfoot> <tr> <td align=\"left\" colspan=\"3\" valign=\"top\">Abbreviations: CI = confidence interval; NR = not reached; PFS = progression-free survival.</td> </tr> </tfoot> <tbody> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"/> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">TUKYSA + Trastuzumab + Pertuzumab</content> </paragraph> <paragraph> <content styleCode=\"bold\">(N = 326)</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Placebo + Trastuzumab + Pertuzumab</content> </paragraph> <paragraph> <content styleCode=\"bold\">(N = 328)</content> </paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">PFS per Investigator</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Number of events (%)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>141 (43)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>191 (58)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Median, months (95% CI)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>24.9 (21.3, NR)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>16.3 (12.6, 18.7)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Hazard ratio (95% CI)<footnote ID=\"_Ref242285450\">Computed using stratification factors: presence or history of brain metastases (yes vs. no), hormone receptor status (positive vs. negative), and diagnosis (<content styleCode=\"italics\">de novo</content> vs. recurrent). Hazard ratio is calculated based on a stratified Cox proportional hazards model.</footnote> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.64 (0.51, 0.80)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> P-value<footnote ID=\"_Ref242285471\">Two-sided P-value is calculated using the stratified log-rank test.</footnote> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>&lt;0.0001</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefSPLSERV-ba33efd4-c755-4c2b-b43f-ec12\" styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 16: Efficacy Results in HER2CLIMB</caption> <col width=\"33%\"/> <col width=\"33%\"/> <col width=\"31%\"/> <tfoot> <tr> <td align=\"left\" colspan=\"3\" valign=\"top\">Abbreviations: BICR = blinded independent central review; CI = confidence interval; CR = complete response; DOR = duration of response; OS = overall survival; ORR = objective response rate; PFS = progression-free survival; PR = partial response.</td> </tr> </tfoot> <tbody> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"/> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">TUKYSA + Trastuzumab + Capecitabine</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Placebo + Trastuzumab + Capecitabine</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">PFS</content> <footnote ID=\"_Ref174024120\">Primary PFS analysis conducted in first 480 randomized patients.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">N = 320</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">N = 160</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Number of events (%)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>178 (56)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>97 (61)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Median, months (95% CI)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>7.8 (7.5, 9.6)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>5.6 (4.2, 7.1)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Hazard ratio (95% CI)<footnote ID=\"_Ref174024129\">Hazard ratio and 95% confidence intervals are based on stratified Cox proportional hazards regression model controlling for stratification factors (presence or history of brain metastases, ECOG status, and region of world).</footnote> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>0.54 (0.42, 0.71)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> P-value<footnote ID=\"_Ref174024135\">Two-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.05.</footnote> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>&lt;0.00001</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">OS</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">N = 410</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">N = 202</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Number of deaths (%)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>130 (32)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>85 (42)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Median, months (95% CI)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>21.9 (18.3, 31.0)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>17.4 (13.6, 19.9)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Hazard ratio (95% CI)<footnoteRef IDREF=\"_Ref174024129\"/> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>0.66 (0.50, 0.87)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> P-value<footnote ID=\"_Ref174024159\">Two-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.0074 for this interim analysis (with 60% of the planned number of events for final analysis).</footnote> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>0.00480</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">PFS<sub>BrainMets</sub> </content> <footnote ID=\"_Ref174024167\">Analysis includes patients with history or presence of parenchymal brain metastases at baseline, including target and non-target lesions. Does not include patients with dural lesions only.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">N =</content> <content styleCode=\"bold\">198</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">N = 93</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Number of events (%)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>106 (53.5)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>51 (54.8)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Median, months (95% CI)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>7.6 (6.2, 9.5)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>5.4 (4.1, 5.7)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> Hazard ratio (95% CI)<footnoteRef IDREF=\"_Ref174024129\"/> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>0.48 (0.34, 0.69)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> P-value<footnote ID=\"_Ref174024182\">Two-sided p-value based on re-randomization procedure (Rosenberger and Lachin 2002) controlling for stratification factors, compared with the allocated alpha of 0.0080 for this interim analysis (with 71% of the planned number of events for final analysis).</footnote> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>&lt;0.00001</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">Confirmed ORR for Patients with Measurable Disease</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">N = 340</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">N = 171</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> ORR (95% CI)<footnote ID=\"_Ref174024189\">Two-sided 95% exact confidence interval, computed using the Clopper-Pearson method (1934).</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>40.6 (35.3, 46.0)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>22.8 (16.7, 29.8)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> CR (%)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>3 (0.9)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>2 (1.2)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> PR (%)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>135 (39.7)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>37 (21.6)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> P-value<footnoteRef IDREF=\"_Ref174024135\"/> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>0.00008</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"> <paragraph> <content styleCode=\"bold\">DOR</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph> Median, months (95% CI)<footnote ID=\"_Ref242351142\">Calculated using the complementary log-log transformation method (Collett, 1994).</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph>8.3 (6.2, 9.7)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"> <paragraph>6.3 (5.8, 8.9)</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefID0ENBBI\" styleCode=\"Noautorules\" width=\"75%\"> <caption>Table 17: Efficacy Results in MOUNTAINEER</caption> <col width=\"43%\"/> <col width=\"44%\"/> <tbody> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">TUKYSA + trastuzumab</content>   <content styleCode=\"bold\">N = 84</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Overall Response Rate (%) (95% CI)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>38 (28, 49)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> CR (%)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3 (3.6)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> PR (%)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>29 (35)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Duration of Response</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>N = 32</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> Median<footnote ID=\"_Ref174025002\">Based on Kaplan-Meier method.</footnote>, months (95% CI)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>12.4 (8.5, 20.5)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> Patients with DOR&#x2265;6 months<footnote ID=\"_Ref174025008\">Based on observed duration of response.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>81%</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> Patients with DOR&#x2265;12 months<footnoteRef IDREF=\"_Ref174025008\"/> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>34%</paragraph> </td> </tr> </tbody> </table>"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"description":["11 DESCRIPTION Tucatinib is a kinase inhibitor. The chemical name is (N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine. The molecular formula is C 26 H 24 N 8 O 2 and the molecular weight is 480.52 g/mol. The chemical structure is as follows: TUKYSA (tucatinib) is supplied as 50 mg and 150 mg film-coated tablets for oral use and contain the following inactive ingredients: Tablet core: copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose. Coating: yellow film coat: polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, talc, and yellow iron oxide non-irradiated. Each TUKYSA 50 mg tablet contains 10.10 mg (0.258 mEq) potassium and 9.21 mg (0.401 mEq) sodium. Each TUKYSA 150 mg tablet contains 30.29 mg (0.775 mEq) potassium and 27.64 mg (1.202 mEq) sodium. structural formula"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • In patients with unresectable or metastatic colorectal cancer, confirm the presence of HER2 protein overexpression and RAS wild-type in tumor specimens prior to the initiation of TUKYSA ( 2.1 ) • Recommended dosage: 300 mg taken orally twice daily with or without food. ( 2.1 ) • For patients with severe hepatic impairment, the recommended dosage is 200 mg orally twice daily. ( 2.4 , 8.7 ) 2.1 Patient Selection Select patients for treatment of unresectable or metastatic colorectal cancer with TUKYSA based on the presence of: • HER2 overexpression or gene amplification [see Clinical Studies (14.2) ]. FDA-authorized tests for the detection of HER2 overexpression and gene amplification in patients with unresectable or metastatic colorectal cancer are not currently available, and • RAS wild-type [see Clinical Studies (14.2) ]. Information on FDA-authorized tests for the detection of RAS mutations in patients with unresectable or metastatic colorectal cancer is available at http://www.fda.gov/CompanionDiagnostics . 2.2 Recommended Dosage The recommended dosages for TUKYSA are listed in Table 1. Table 1: Recommended Dosage Indication Recommended TUKYSA Dosage Duration of Therapy Unresectable or Metastatic Breast Cancer Maintenance Treatment of HER2‑Positive Breast Cancer 300 mg orally twice daily in combination with trastuzumab and pertuzumab. Refer to the Prescribing Information of combination agents for dosing and administration information. Until disease progression or unacceptable toxicity. Unresectable or Metastatic Breast Cancer HER2-Positive Breast Cancer 300 mg orally twice daily in combination with trastuzumab and capecitabine. When given in combination with TUKYSA, the recommended dosage of capecitabine is 1000 mg/m 2 orally twice daily taken within 30 minutes after a meal. TUKYSA and capecitabine can be taken at the same time. Until disease progression or unacceptable toxicity. Unresectable or Metastatic Colorectal Cancer 300 mg orally twice daily in combination with trastuzumab. Until disease progression or unacceptable toxicity. Administration Instructions Advise patients to swallow TUKYSA tablets whole and not to chew, crush, or split prior to swallowing. Advise patients not to ingest a tablet if it is broken, cracked, or not otherwise intact. Advise patients to take TUKYSA approximately 12 hours apart and at the same time each day with or without a meal [see Clinical Pharmacology (12.3) ] . If the patient vomits or misses a dose of TUKYSA, instruct the patient to take the next dose at its usual scheduled time. 2.3 Dosage Modifications for Adverse Reactions The recommended TUKYSA dose reductions and dosage modifications for adverse reactions are provided in Tables 2 and 3. Refer to the Prescribing Information of combination agents for information about dosage modifications for these drugs. Table 2: Recommended TUKYSA Dose Reductions for Adverse Reactions Dose Reduction Recommended TUKYSA Dosage First 250 mg orally twice daily Second 200 mg orally twice daily Third 150 mg orally twice daily Permanently discontinue TUKYSA in patients unable to tolerate 150 mg orally twice daily. Table 3: Recommended TUKYSA Dosage Modifications for Adverse Reactions Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal. Adverse Reaction Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03. Severity TUKYSA Dosage Modification Hepatotoxicity [see Warnings and Precautions (5.1) ] ALT or AST >3 × ULN AND Bilirubin >2 × ULN Permanently discontinue TUKYSA. ALT or AST >3 × ULN AND Bilirubin > ULN to ≤2 × ULN Repeat testing within 48-72 hours to determine if worsening. Grade 2 bilirubin (>1.5 to 3 × ULN) Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the same dose. Grade 3 ALT or AST (>5 to 20 × ULN) Hold TUKYSA and repeat testing within 48-72 hours to determine if worsening. Consider permanent discontinuation or hold until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose. Permanently discontinue TUKYSA for recurrent Grade 3 ALT or AST. Grade 3 bilirubin (>3 to 10 × ULN) Hold until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose. Grade 4 ALT or AST (>20 × ULN) OR Grade 4 bilirubin (>10 × ULN) Permanently discontinue TUKYSA. Diarrhea [see Warnings and Precautions (5.2) ] Grade 3 without antidiarrheal treatment Initiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the same dose. Grade 3 with antidiarrheal treatment Initiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose. Grade 4 Permanently discontinue TUKYSA. Other adverse reactions [see Adverse Reactions (6.1) ] Grade 3 Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose. Grade 4 Permanently discontinue TUKYSA. 2.4 Dosage Modifications for Severe Hepatic Impairment For patients with severe hepatic impairment (Child-Pugh C), reduce the recommended dosage to 200 mg orally twice daily [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] . 2.5 Dosage Modifications for Concomitant Use with Strong CYP2C8 Inhibitors Avoid concomitant use of strong CYP2C8 inhibitors with TUKYSA. If concomitant use with a strong CYP2C8 inhibitor cannot be avoided, reduce the recommended dosage to 100 mg orally twice daily. After discontinuation of the strong CYP2C8 inhibitor for 3 elimination half-lives, resume the TUKYSA dose that was taken prior to initiating the inhibitor [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ] ."],"dosage_and_administration_table":["<table styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 1: Recommended Dosage</caption> <col width=\"33%\"/> <col width=\"33%\"/> <col width=\"33%\"/> <tbody> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\"> <content styleCode=\"bold\">Indication</content> </content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\"> <content styleCode=\"bold\">Recommended TUKYSA Dosage</content> </content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\"> <content styleCode=\"bold\">Duration of Therapy </content> </content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\"> <content styleCode=\"underline\">Unresectable or Metastatic Breast Cancer</content> </content> </paragraph> <paragraph> <content styleCode=\"xmChange\"> <content styleCode=\"italics\">Maintenance Treatment of HER2&#x2011;Positive Breast Cancer</content> </content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\">300 mg orally twice daily in combination with trastuzumab and pertuzumab.</content> <footnote ID=\"_Ref242281261\">Refer to the Prescribing Information of combination agents for dosing and administration information.</footnote> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\">Until disease progression or unacceptable toxicity.</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">Unresectable or Metastatic Breast Cancer</content> </paragraph> <paragraph> <content styleCode=\"italics\">HER2-Positive Breast Cancer</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>300 mg orally twice daily in combination with trastuzumab and capecitabine.<footnoteRef IDREF=\"_Ref242281261\"/>    When given in combination with TUKYSA, the recommended dosage of capecitabine is 1000 mg/m<sup>2</sup> orally twice daily taken within 30 minutes after a meal. TUKYSA and capecitabine can be taken at the same time.</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Until disease progression or unacceptable toxicity.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">Unresectable or Metastatic Colorectal Cancer</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>300 mg orally twice daily in combination with trastuzumab.<footnoteRef IDREF=\"_Ref242281261\"/> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Until disease progression or unacceptable toxicity.</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefID0EARAE\" styleCode=\"Noautorules\" width=\"60%\"> <caption>Table 2: Recommended TUKYSA Dose Reductions for Adverse Reactions</caption> <col width=\"34%\"/> <col width=\"36%\"/> <tbody> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Dose Reduction</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Recommended TUKYSA Dosage</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>First</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>250 mg orally twice daily</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Second</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>200 mg orally twice daily</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Third</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>150 mg orally twice daily</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefSPLSERV-37a9564c-39cf-46bd-82c2-f90a\" styleCode=\"Noautorules\" width=\"100.04%\"> <caption>Table 3: Recommended TUKYSA Dosage Modifications for Adverse Reactions</caption> <col width=\"22%\"/> <col width=\"41%\"/> <col width=\"38%\"/> <tfoot> <tr> <td align=\"left\" colspan=\"3\" valign=\"top\">Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal.</td> </tr> </tfoot> <tbody> <tr> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Adverse Reaction</content> <footnote ID=\"_Ref242282037\">Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.</footnote> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Severity</content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">TUKYSA Dosage Modification</content> </paragraph> </td> </tr> <tr> <td rowspan=\"6\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Hepatotoxicity <content styleCode=\"italics\">[see <linkHtml href=\"#ID_15dc5fad-9ece-481b-8f94-079b3ce7ff10\">Warnings and Precautions (5.1)</linkHtml>]</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>ALT or AST &gt;3 &#xD7; ULN   AND   Bilirubin &gt;2 &#xD7; ULN</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Permanently discontinue TUKYSA.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\">ALT or AST &gt;3 &#xD7; ULN   AND   Bilirubin &gt; ULN to &#x2264;2 &#xD7; ULN </content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\">Repeat testing within 48-72 hours to determine if worsening.</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Grade 2 bilirubin (&gt;1.5 to 3 &#xD7; ULN) </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Hold TUKYSA until recovery to &#x2264; Grade 1, then resume TUKYSA at the same dose.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Grade 3 ALT or AST (&gt;5 to 20 &#xD7; ULN) </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\">Hold TUKYSA and repeat testing within 48-72 hours to determine if worsening. Consider permanent discontinuation or hold until recovery to &#x2264; Grade 1, then resume TUKYSA at the next lower dose. Permanently discontinue TUKYSA for recurrent Grade 3 ALT or AST.</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\">Grade 3 bilirubin (&gt;3 to 10 &#xD7; ULN)</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"xmChange\">Hold until recovery to &#x2264; Grade 1, then resume TUKYSA at the next lower dose.</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Grade 4 ALT or AST (&gt;20 &#xD7; ULN)   OR   Grade 4 bilirubin (&gt;10 &#xD7; ULN)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Permanently discontinue TUKYSA.</paragraph> </td> </tr> <tr> <td rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Diarrhea <content styleCode=\"italics\">[see <linkHtml href=\"#ID_48f2eb1d-b7d6-4a5b-8a39-bead01de0cbb\">Warnings and Precautions (5.2)</linkHtml>]</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Grade 3 without antidiarrheal treatment</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Initiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to &#x2264; Grade 1, then resume TUKYSA at the same dose.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Grade 3 with antidiarrheal treatment</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Initiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to &#x2264; Grade 1, then resume TUKYSA at the next lower dose.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Grade 4 </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Permanently discontinue TUKYSA.</paragraph> </td> </tr> <tr> <td rowspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>Other adverse reactions <content styleCode=\"italics\">[see <linkHtml href=\"#ID_09fa466c-e920-4c7d-aa5b-df1f35dad041\">Adverse Reactions (6.1)</linkHtml>]</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Grade 3</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Hold TUKYSA until recovery to &#x2264; Grade 1, then resume TUKYSA at the next lower dose.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Grade 4</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Permanently discontinue TUKYSA.</paragraph> </td> </tr> </tbody> </table>"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets: • 50 mg: round, yellow, film-coated, debossed with “TUC” on one side and “50” on the other side. • 150 mg: oval-shaped, yellow, film-coated, debossed with “TUC” on one side and “150” on the other side. Tablets: 50 mg and 150 mg. ( 3 )"],"drug_and_or_laboratory_test_interactions":["7.1 Effects of Other Drugs on TUKYSA Table 10 summarizes the effect of other drugs on TUKYSA. Table 10: Drug Interactions that Affect TUKYSA Strong CYP3A Inducers or Moderate CYP2C8 Inducers Clinical Impact Concomitant use of TUKYSA with a strong CYP3A or moderate CYP2C8 inducer decreased tucatinib plasma concentrations [see Clinical Pharmacology (12.3) ] , which may reduce TUKYSA activity. Management Avoid concomitant use of TUKYSA with a strong CYP3A inducer or a moderate CYP2C8 inducer. Strong or Moderate CYP2C8 Inhibitors Clinical Impact Concomitant use of TUKYSA with a strong CYP2C8 inhibitor increased tucatinib plasma concentrations [see Clinical Pharmacology (12.3) ] , which may increase the risk of TUKYSA toxicity. Management Avoid concomitant use of TUKYSA with a strong CYP2C8 inhibitor [see Dosage and Administration (2.5) ] . Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.","7.2 Effects of TUKYSA on Other Drugs Table 11 summarizes the effect of TUKYSA on other drugs. Table 11: TUKYSA Drug Interactions that Affect Other Drugs CYP3A Substrates Clinical Impact Concomitant use of TUKYSA with a CYP3A substrate increased the plasma concentrations of CYP3A substrate [see Clinical Pharmacology (12.3) ] , which may increase the toxicity associated with a CYP3A substrate. Management Avoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling. P-glycoprotein (P-gp) Substrates Clinical Impact Concomitant use of TUKYSA with a P-gp substrate increased the plasma concentrations of P-gp substrate [see Clinical Pharmacology (12.3) ] , which may increase the toxicity associated with a P-gp substrate. Management Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities."],"drug_and_or_laboratory_test_interactions_table":["<table ID=\"_RefID0E5WBG\" styleCode=\"Noautorules\" width=\"85%\"> <caption>Table 10: Drug Interactions that Affect TUKYSA</caption> <col width=\"49%\"/> <col width=\"49%\"/> <tbody> <tr> <td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Strong CYP3A Inducers or Moderate CYP2C8 Inducers</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Clinical Impact</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Concomitant use of TUKYSA with a strong CYP3A or moderate CYP2C8 inducer decreased tucatinib plasma concentrations <content styleCode=\"italics\">[see <linkHtml href=\"#ID_a7be1577-4f6f-461c-ac9f-9af168389771\">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may reduce TUKYSA activity.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Management</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Avoid concomitant use of TUKYSA with a strong CYP3A inducer or a moderate CYP2C8 inducer. </paragraph> </td> </tr> <tr> <td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Strong or Moderate CYP2C8 Inhibitors</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Clinical Impact</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Concomitant use of TUKYSA with a strong CYP2C8 inhibitor increased tucatinib plasma concentrations <content styleCode=\"italics\">[see <linkHtml href=\"#ID_a7be1577-4f6f-461c-ac9f-9af168389771\">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may increase the risk of TUKYSA toxicity.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Management</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Avoid concomitant use of TUKYSA with a strong CYP2C8 inhibitor <content styleCode=\"italics\">[see <linkHtml href=\"#ID_ed04b46a-0b0c-4fca-a713-932693098045\">Dosage and Administration (2.5)</linkHtml>]</content>. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors. </paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefSPLSERV-25ba68fe-0485-4937-8152-9467\" styleCode=\"Noautorules\" width=\"85%\"> <caption>Table 11: TUKYSA Drug Interactions that Affect Other Drugs</caption> <col width=\"49%\"/> <col width=\"49%\"/> <tbody> <tr> <td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">CYP3A Substrates</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Clinical Impact</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Concomitant use of TUKYSA with a CYP3A substrate increased the plasma concentrations of CYP3A substrate <content styleCode=\"italics\">[see <linkHtml href=\"#ID_a7be1577-4f6f-461c-ac9f-9af168389771\">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may increase the toxicity associated with a CYP3A substrate.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Management</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Avoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling.</paragraph> </td> </tr> <tr> <td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">P-glycoprotein (P-gp) Substrates</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Clinical Impact</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Concomitant use of TUKYSA with a P-gp substrate increased the plasma concentrations of P-gp substrate <content styleCode=\"italics\">[see <linkHtml href=\"#ID_a7be1577-4f6f-461c-ac9f-9af168389771\">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may increase the toxicity associated with a P-gp substrate.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Management</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.</paragraph> </td> </tr> </tbody> </table>"],"drug_interactions":["7 DRUG INTERACTIONS • Strong CYP3A Inducers or Moderate CYP2C8 Inducers : Avoid concomitant use. ( 7.1 ) • Strong CYP2C8 Inhibitors : Avoid concomitant use; reduce TUKYSA dose if concomitant use cannot be avoided. ( 2.5 , 7.1 ) • CYP3A Substrates : Avoid concomitant use with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. ( 7.2 ) • P-gp Substrates : Consider reducing the dose of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. ( 7.2 ) 7.1 Effects of Other Drugs on TUKYSA Table 10 summarizes the effect of other drugs on TUKYSA. Table 10: Drug Interactions that Affect TUKYSA Strong CYP3A Inducers or Moderate CYP2C8 Inducers Clinical Impact Concomitant use of TUKYSA with a strong CYP3A or moderate CYP2C8 inducer decreased tucatinib plasma concentrations [see Clinical Pharmacology (12.3) ] , which may reduce TUKYSA activity. Management Avoid concomitant use of TUKYSA with a strong CYP3A inducer or a moderate CYP2C8 inducer. Strong or Moderate CYP2C8 Inhibitors Clinical Impact Concomitant use of TUKYSA with a strong CYP2C8 inhibitor increased tucatinib plasma concentrations [see Clinical Pharmacology (12.3) ] , which may increase the risk of TUKYSA toxicity. Management Avoid concomitant use of TUKYSA with a strong CYP2C8 inhibitor [see Dosage and Administration (2.5) ] . Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors. 7.2 Effects of TUKYSA on Other Drugs Table 11 summarizes the effect of TUKYSA on other drugs. Table 11: TUKYSA Drug Interactions that Affect Other Drugs CYP3A Substrates Clinical Impact Concomitant use of TUKYSA with a CYP3A substrate increased the plasma concentrations of CYP3A substrate [see Clinical Pharmacology (12.3) ] , which may increase the toxicity associated with a CYP3A substrate. Management Avoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling. P-glycoprotein (P-gp) Substrates Clinical Impact Concomitant use of TUKYSA with a P-gp substrate increased the plasma concentrations of P-gp substrate [see Clinical Pharmacology (12.3) ] , which may increase the toxicity associated with a P-gp substrate. Management Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities."],"drug_interactions_table":["<table ID=\"_RefID0E5WBG\" styleCode=\"Noautorules\" width=\"85%\"> <caption>Table 10: Drug Interactions that Affect TUKYSA</caption> <col width=\"49%\"/> <col width=\"49%\"/> <tbody> <tr> <td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Strong CYP3A Inducers or Moderate CYP2C8 Inducers</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Clinical Impact</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Concomitant use of TUKYSA with a strong CYP3A or moderate CYP2C8 inducer decreased tucatinib plasma concentrations <content styleCode=\"italics\">[see <linkHtml href=\"#ID_a7be1577-4f6f-461c-ac9f-9af168389771\">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may reduce TUKYSA activity.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Management</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Avoid concomitant use of TUKYSA with a strong CYP3A inducer or a moderate CYP2C8 inducer. </paragraph> </td> </tr> <tr> <td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Strong or Moderate CYP2C8 Inhibitors</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Clinical Impact</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Concomitant use of TUKYSA with a strong CYP2C8 inhibitor increased tucatinib plasma concentrations <content styleCode=\"italics\">[see <linkHtml href=\"#ID_a7be1577-4f6f-461c-ac9f-9af168389771\">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may increase the risk of TUKYSA toxicity.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Management</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Avoid concomitant use of TUKYSA with a strong CYP2C8 inhibitor <content styleCode=\"italics\">[see <linkHtml href=\"#ID_ed04b46a-0b0c-4fca-a713-932693098045\">Dosage and Administration (2.5)</linkHtml>]</content>. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors. </paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefSPLSERV-25ba68fe-0485-4937-8152-9467\" styleCode=\"Noautorules\" width=\"85%\"> <caption>Table 11: TUKYSA Drug Interactions that Affect Other Drugs</caption> <col width=\"49%\"/> <col width=\"49%\"/> <tbody> <tr> <td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">CYP3A Substrates</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Clinical Impact</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Concomitant use of TUKYSA with a CYP3A substrate increased the plasma concentrations of CYP3A substrate <content styleCode=\"italics\">[see <linkHtml href=\"#ID_a7be1577-4f6f-461c-ac9f-9af168389771\">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may increase the toxicity associated with a CYP3A substrate.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Management</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Avoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage in accordance with approved product labeling.</paragraph> </td> </tr> <tr> <td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">P-glycoprotein (P-gp) Substrates</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Clinical Impact</content> </paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>Concomitant use of TUKYSA with a P-gp substrate increased the plasma concentrations of P-gp substrate <content styleCode=\"italics\">[see <linkHtml href=\"#ID_a7be1577-4f6f-461c-ac9f-9af168389771\">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may increase the toxicity associated with a P-gp substrate.</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"italics\">Management</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.</paragraph> </td> </tr> </tbody> </table>"],"effective_time":"20261014","geriatric_use":["8.5 Geriatric Use In HER2CLIMB-05, 51 patients who received TUKYSA were ≥65 years of age of whom 12 patients were ≥75 years of age. The incidence of ≥ Grade 3 adverse reactions was 57% in patients ≥65 years of age compared to 40% in patients <65 years of age. There were no overall differences in the effectiveness of TUKYSA in patients ≥65 years of age compared to younger patients. There were too few patients ≥75 years of age to assess differences in effectiveness or safety. In HER2CLIMB, 82 patients who received TUKYSA were ≥65 years of age, of whom 8 patients were ≥75 years of age. The incidence of serious adverse reactions in those receiving TUKYSA was 34% in patients ≥65 years of age compared to 24% in patients <65 years of age. The most frequent serious adverse reactions in patients ≥65 years of age who received TUKYSA were diarrhea (9%), vomiting (6%), and nausea (5%). There were no observed overall differences in the effectiveness of TUKYSA in patients ≥65 years of age compared to younger patients. There were too few patients ≥75 years of age to assess differences in effectiveness or safety. In MOUNTAINEER, 12 patients were ≥65 years of age. There were too few patients ≥65 years of age to assess differences in effectiveness or safety."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied TUKYSA 50 mg tablets are supplied as yellow, film-coated, round tablets containing 50 mg of tucatinib. Each tablet is debossed with “TUC” on one side and “50” on the other side, and is packaged as follows: 50 mg tablets: bottle of 60 tablets (NDC 51144-001-60) TUKYSA 150 mg tablets are supplied as yellow, film-coated, oval-shaped tablets containing 150 mg of tucatinib. Each tablet is debossed with “TUC” on one side and “150” on the other side, and is packaged as follows: 150 mg tablets: bottle of 60 tablets (NDC 51144-002-60) 150 mg tablets: bottle of 120 tablets (NDC 51144-002-12) Store at controlled room temperature at 20ºC to 25ºC (68ºF to 77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Dispense to patient in original container only. Store in original container to protect from moisture. Replace cap securely each time after opening. Do not discard desiccant. Once opened, use within 3 months. Discard any unused tablets 3 months after opening the bottle."],"id":"8afb8c49-b2fe-43cb-94bf-166f8c139a72","indications_and_usage":["1 INDICATIONS AND USAGE TUKYSA is a kinase inhibitor indicated: • in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. ( 1.1 ) • in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. ( 1.1 ) • in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 1.1 Unresectable or Metastatic Breast Cancer Maintenance Treatment of HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. 1.2 Unresectable or Metastatic Colorectal Cancer TUKYSA is indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Hepatotoxicity • Inform patients that TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge, and that they should report signs and symptoms of liver dysfunction to their healthcare provider immediately [see Warnings and Precautions (5.1) ] . Diarrhea • Inform patients that TUKYSA can cause severe diarrhea including dehydration, hypotension, acute kidney injury and death. Instruct patients on how to manage diarrhea and to inform their healthcare provider immediately if there is any change in bowel patterns [see Warnings and Precautions (5.2) ] . Embryo-Fetal Toxicity • Inform pregnant women and females of reproductive potential of the risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1) ]. • Advise females of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose [see Use in Specific Populations (8.3) ] . • Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose [see Use in Specific Populations (8.3) ] . • Refer to the Prescribing Information of combination agents for pregnancy and contraception information. When TUKYSA is used in combination, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products. Lactation • Advise women not to breastfeed during treatment with TUKYSA and for 1 week after the last dose [see Use in Specific Populations (8.2) ] . Refer to the Prescribing Information of combination agents for lactation information. When TUKYSA is used in combination, advise patients not to breastfeed during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products. Infertility • Advise males and females of reproductive potential that TUKYSA may impair fertility [see Use in Specific Populations (8.3) ] . Refer to the Prescribing Information of combination agents for infertility information. Manufactured for: Seagen Inc. Bothell, WA 98021 1-855-4SEAGEN TUKYSA, Seagen, and are US registered trademarks of Seagen Inc. © 2026 Seagen Inc., Bothell, WA 98021. All rights reserved. This product’s labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com . LAB-1593-1.0 logo small logo"],"mechanism_of_action":["12.1 Mechanism of Action Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro , tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo , tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with tucatinib. Tucatinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay. Tucatinib was not clastogenic in either an in vitro chromosome aberration assay or an in vivo mouse bone marrow micronucleus assay. Fertility studies in animals have not been conducted. In repeat-dose toxicity studies up to 13 weeks duration, decreased corpora lutea/corpus luteum cyst, increased interstitial cells of the ovary, atrophy of the uterus, and mucification of the vagina were observed in female rats at doses ≥6 mg/kg/day (approximately 0.1 times the human exposure at the recommended dose based on AUC). Atrophy and edema of the testes and oligospermia/germ cell debris in the epididymides were observed in male rats at ≥120 mg/kg/day (approximately 13 times the human exposure at the recommended dose based on AUC)."],"openfda":{"application_number":["NDA213411"],"brand_name":["TUKYSA"],"generic_name":["TUCATINIB"],"is_original_packager":[true],"manufacturer_name":["SEAGEN INC."],"nui":["N0000175605","N0000020001","N0000190114","N0000185503","N0000187062"],"package_ndc":["51144-001-60","51144-002-60","51144-002-12"],"pharm_class_epc":["Kinase Inhibitor [EPC]"],"pharm_class_moa":["Tyrosine Kinase Inhibitors [MoA]","Cytochrome P450 3A Inhibitors [MoA]","P-Glycoprotein Inhibitors [MoA]","Cytochrome P450 2C8 Inhibitors [MoA]"],"product_ndc":["51144-001","51144-002"],"product_type":["HUMAN PRESCRIPTION DRUG"],"route":["ORAL"],"rxcui":["2361290","2361296","2361298","2361300"],"spl_id":["8afb8c49-b2fe-43cb-94bf-166f8c139a72"],"spl_set_id":["f27eb1b9-b7fc-424e-988f-84dd7bb195a3"],"substance_name":["TUCATINIB"],"unii":["234248D0HH"]},"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 51144- 001 -60 Rx Only TUKYSA ® (tucatinib) tablets 50 mg* Attention: Dispense and store Tukysa in original container to protect from moisture. Seagen ® 60 Tablets * Each tablet contains 50 mg tucatinib. Recommended Dosage: See prescribing information Store at controlled room temperature, 20°C to 25°C (68° to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. KEEP OUT OF REACH OF CHILDREN Discard unused tablets 3 months after opening. Mfg for: Seagen Inc. Bothell, WA 98021 USA TUKYSA and its logo are US registered trademarks of Seagen Inc. ©2023 Seagen Inc. All rights reserved. Printed in USA 00000000 GTIN 00351144001607 LOT: 123456 EXP: MMMYYYY SN: 12345678901234 NDC 51144- 002 -60 Rx Only TUKYSA ® (tucatinib) tablets 150 mg* Attention: Dispense and store Tukysa in original container to protect from moisture. Seagen ® 60 Tablets * Each tablet contains 150 mg tucatinib. Recommended Dosage: See prescribing information Store at controlled room temperature, 20°C to 25°C (68° to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. KEEP OUT OF REACH OF CHILDREN Discard unused tablets 3 months after opening. Mfg for: Seagen Inc. Bothell, WA 98021 USA TUKYSA and its logo are US registered trademarks of Seagen Inc. ©2023 Seagen Inc. All rights reserved. Printed in USA 00000000 GTIN 00351144002604 LOT: 123456 EXP: MMMYYYY SN: 12345678901234 NDC 51144- 002 -12 Rx Only TUKYSA ® (tucatinib) tablets 150 mg* Attention: Dispense and store Tukysa in original container to protect from moisture. SeaGen ® 120 Tablets * Each tablet contains 150 mg tucatinib. Recommended Dosage: See prescribing information Store at controlled room temperature, 20°C to 25°C (68° to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. KEEP OUT OF REACH OF CHILDREN Discard unused tablets 3 months after opening. Mfg for: Seagen Inc. Bothell, WA 98021 USA TUKYSA and its logo are US registered trademarks of Seagen Inc. ©2021 Seagen Inc. All rights reserved. Printed in USA 1204-02 GTIN 00351144002604 LOT: 123456 EXP: MMMYYYY SN: 12345678901234 50 mg Label 150 mg Label 60 count 150 mg Label 120 count"],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of TUKYSA in pediatric patients have not been established."],"pharmacodynamics":["12.2 Pharmacodynamics Exposure-Response Relationship Tucatinib exposure-response relationships and the time course of pharmacodynamics response have not been fully characterized. Cardiac Electrophysiology No large mean increase in QTc (i.e., >20 ms) was detected following treatment with TUKYSA at the recommended dose of 300 mg taken orally twice daily."],"pharmacokinetics":["12.3 Pharmacokinetics Tucatinib AUC 0-INF and C max increased proportionally over a dosage range from 50 mg to 300 mg (0.17 to 1 times the approved recommended dosage). Time to steady state was approximately 4 days. Steady-state pharmacokinetic parameters following administration of TUKYSA 300 mg twice daily for 7 days in patients with mBC and mCRC are described in Table 12. The geometric mean (CV%) tucatinib AUC accumulation ratios ranged from 2.0 (26) fold to 2.5 (28) fold. Table 12: Tucatinib C max and AUC Tumor Type AUC ss (ng*h/mL) C max,ss (ng/mL) C trough,ss (ng/mL) mBC 5620 (43) 747 (45) 288 (59) mCRC 3370 (49) 405 (45) 197 (63) Absorption The median time to peak plasma concentration of tucatinib was approximately 2 hours (range 1 to 4 hours). Effects of Food Following administration of a single oral dose of TUKYSA in 11 subjects after a high-fat meal (approximately 58% fat, 26% carbohydrate, and 16% protein), the mean AUC 0-INF increased by 1.5-fold, the T max shifted from 1.5 hours to 4 hours, and C max was unaltered. The effect of food on the pharmacokinetics of tucatinib was not clinically meaningful. Distribution The geometric mean (CV%) apparent volume of distribution of tucatinib at steady-state were 903 (42) L and 829 (21) L in patients with mBC and mCRC, respectively. The plasma protein binding was 97.1% at clinically relevant concentrations. At steady-state, concentrations of tucatinib and its metabolite ONT-993 in the cerebrospinal fluid were comparable to unbound plasma concentrations. Elimination At steady-state, tucatinib effective half-life was approximately 11.9 hours and geometric mean (CV%) apparent clearance was 53 (43) L/h in patients with mBC. Tucatinib effective half-life was approximately 16.4 hours and geometric mean (CV%) apparent clearance was 89 (49) L/h in patients with mCRC. Metabolism Tucatinib is metabolized primarily by CYP2C8 and to a lesser extent via CYP3A. Excretion Following a single oral dose of 300 mg radiolabeled tucatinib, approximately 86% of the total radiolabeled dose was recovered in feces (16% of the administered dose as unchanged tucatinib) and 4.1% in urine with an overall total recovery of 90% within 13 days post-dose. In plasma, approximately 76% of the plasma radioactivity was unchanged, 19% was attributed to identified metabolites, and approximately 5% was unassigned. Specific Populations Age (18-77 years), albumin (19 to 52 g/L), creatinine clearance (CLcr: 60 to 89 mL/min (n = 63); CLcr 30 to 59 mL/min (n = 6)), body weight (41 to 146 kg), sex (male (n = 170), female (n = 113)) and race (White (n = 205), Black (n = 37), or Asian (n = 25)) did not have a clinically meaningful effect on tucatinib exposure. Renal Impairment No clinically significant differences in the pharmacokinetics of tucatinib were observed in patients with mild to moderate renal impairment (CLcr: 30 to 89 mL/min by Cockcroft-Gault). The effect of severe renal impairment (CLcr: <30 mL/min) on the pharmacokinetics of tucatinib is unknown. Hepatic Impairment Mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment had no clinically relevant effect on tucatinib exposure. Tucatinib AUC 0-INF was increased by 1.6 fold in subjects with severe (Child-Pugh C) hepatic impairment compared to subjects with normal hepatic function. Drug Interaction Studies Clinical Studies Table 13: Effect of Other Drugs on TUKYSA Concomitant Drug (Dose) TUKYSA Dose Ratio (90% CI) of Tucatinib Exposure With and Without Concomitant Drug C max AUC Strong CYP3A Inhibitor Itraconazole (200 mg BID) 300 mg single dose 1.3 (1.2, 1.4) 1.3 (1.3, 1.4) Strong CYP3A/Moderate 2C8 Inducer Rifampin (600 mg once daily) 0.6 (0.5, 0.8) 0.5 (0.4, 0.6) Strong CYP2C8 Inhibitor Gemfibrozil (600 mg BID) 1.6 (1.5, 1.8) 3.0 (2.7, 3.5) Table 14: Effect of TUKYSA on Other Drugs Concomitant Drug (Dose) TUKYSA Dose Ratio (90% CI) of Exposure Measures of Concomitant Drug with/without Tucatinib C max AUC CYP2C8 Substrate Repaglinide (0.5 mg single dose) 300 mg twice daily 1.7 (1.4, 2.1) 1.7 (1.5, 1.9) CYP3A Substrate Midazolam (2 mg single dose) 3.0 (2.6, 3.4) 5.7 (5.0, 6.5) P-gp Substrate Digoxin (0.5 mg single dose) 2.4 (1.9, 2.9) 1.5 (1.3, 1.7) MATE1/2-K substrate Tucatinib reduced the renal clearance of metformin without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C. Metformin (850 mg single dose) 1.1 (1.0, 1.2) 1.4 (1.2, 1.5) No clinically significant difference in the pharmacokinetics of tucatinib were observed when used concomitantly with omeprazole (proton pump inhibitor) or tolbutamide (sensitive CYP2C9 substrate). In Vitro Studies Cytochrome P450 (CYP) Enzymes: Tucatinib is a reversible inhibitor of CYP2C8 and CYP3A and a time-dependent inhibitor of CYP3A, but is not an inhibitor of CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6. Uridine diphosphate (UDP)-glucuronosyl transferase (UGT) Enzymes: Tucatinib is not an inhibitor of UGT1A1. Transporter Systems: Tucatinib is a substrate of P-gp and BCRP, but is not a substrate of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, or BSEP. Tucatinib inhibits MATE1/MATE2-K-mediated transport of metformin and OCT2/MATE1-mediated transport of creatinine. The observed serum creatinine increase in clinical studies with tucatinib is due to inhibition of tubular secretion of creatinine via OCT2 and MATE1."],"pharmacokinetics_table":["<table ID=\"_RefID0ERGAI\" styleCode=\"Noautorules\" width=\"100%\"> <caption>Table 12: Tucatinib C<sub>max</sub> and AUC</caption> <col width=\"25%\"/> <col width=\"25%\"/> <col width=\"25%\"/> <col width=\"25%\"/> <tbody> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Tumor Type</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">AUC<sub>ss </sub>(ng*h/mL)</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">C<sub>max,ss </sub>(ng/mL)</content> </paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">C<sub>trough,ss </sub>(ng/mL)</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph>mBC</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>5620 (43)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>747 (45)</paragraph> </td> <td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>288 (59)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>mCRC</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>3370 (49)</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>405 (45)</paragraph> </td> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>197 (63)</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefID0EOKAI\" styleCode=\"Noautorules\" width=\"90%\"> <caption>Table 13: Effect of Other Drugs on TUKYSA</caption> <col width=\"36%\"/> <col width=\"20%\"/> <col width=\"22%\"/> <col width=\"22%\"/> <tbody> <tr> <td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Concomitant Drug</content>   <content styleCode=\"bold\">(Dose)</content> </paragraph> </td> <td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">TUKYSA Dose</content> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Ratio (90% CI) of Tucatinib</content>   <content styleCode=\"bold\">Exposure With and Without</content>   <content styleCode=\"bold\">Concomitant Drug</content> </paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">C<sub>max</sub> </content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">AUC</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">Strong CYP3A Inhibitor</content>  Itraconazole (200 mg BID)</paragraph> </td> <td align=\"center\" rowspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>300 mg single dose</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.3 (1.2, 1.4)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.3 (1.3, 1.4)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">Strong CYP3A/Moderate 2C8 Inducer</content>  Rifampin (600 mg once daily)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.6 (0.5, 0.8)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>0.5 (0.4, 0.6)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">Strong CYP2C8 Inhibitor</content>  Gemfibrozil (600 mg BID)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>1.6 (1.5, 1.8)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>3.0 (2.7, 3.5)</paragraph> </td> </tr> </tbody> </table>","<table ID=\"_RefID0EEOAI\" styleCode=\"Noautorules\" width=\"90%\"> <caption>Table 14: Effect of TUKYSA on Other Drugs</caption> <col width=\"35%\"/> <col width=\"22%\"/> <col width=\"22%\"/> <col width=\"22%\"/> <tbody> <tr> <td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Concomitant Drug</content>   <content styleCode=\"bold\">(Dose)</content> </paragraph> </td> <td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">TUKYSA Dose</content> </paragraph> </td> <td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"> <paragraph> <content styleCode=\"bold\">Ratio (90% CI) of Exposure</content>   <content styleCode=\"bold\">Measures of Concomitant Drug</content>   <content styleCode=\"bold\">with/without Tucatinib</content> </paragraph> </td> </tr> <tr> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">C<sub>max</sub> </content> </paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">AUC</content> </paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">CYP2C8 Substrate</content>  Repaglinide (0.5 mg single dose)</paragraph> </td> <td align=\"center\" rowspan=\"4\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"> <paragraph>300 mg twice daily</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.7 (1.4, 2.1)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.7 (1.5, 1.9)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">CYP3A Substrate</content>  Midazolam (2 mg single dose)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>3.0 (2.6, 3.4)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>5.7 (5.0, 6.5)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">P-gp Substrate  </content>Digoxin (0.5 mg single dose)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>2.4 (1.9, 2.9)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph>1.5 (1.3, 1.7)</paragraph> </td> </tr> <tr> <td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"underline\">MATE1/2-K substrate</content> <footnote ID=\"_Ref171610446\">Tucatinib reduced the renal clearance of metformin without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C.</footnote>  Metformin (850 mg single dose)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>1.1 (1.0, 1.2)</paragraph> </td> <td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph>1.4 (1.2, 1.5)</paragraph> </td> </tr> </tbody> </table>"],"pregnancy":["8.1 Pregnancy Risk Summary TUKYSA is used in combination with other agents. Refer to the Prescribing Information of combination agents for pregnancy information. Based on findings in animals and its mechanism of action, TUKYSA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available human data on TUKYSA use in pregnant women to inform a drug-associated risk. In animal reproduction studies, administration of tucatinib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal mortality, reduced fetal weight and fetal abnormalities at maternal exposures ≥1.3 times the human exposure (AUC) at the recommended dose (see Data ) . Advise pregnant women and females of reproductive potential of the potential risk to the fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Data Animal Data In pilot embryo-fetal development studies, pregnant rats and rabbits received oral doses of tucatinib up to 150 mg/kg/day during the period of organogenesis. In rats, oral administration of tucatinib resulted in maternal toxicity (body weight loss, reduced body weight gain, low food consumption) at doses ≥90 mg/kg/day. Fetal effects included reduced number of live fetuses, decreased fetal weight, and fetal abnormalities (increase in skeletal variations, incomplete ossification) at ≥90 mg/kg/day (approximately 3.5 times the human exposure at the recommended dose based on AUC). In rabbits, oral administration of tucatinib resulted in increased resorptions, decreased percentages of live fetuses, and skeletal, visceral, and external malformations in fetuses at doses ≥90 mg/kg/day (1.3 times the human exposure at the recommended dose based on AUC). Fetal abnormalities included domed head, brain dilation, incomplete ossification of frontal and parietal bones, and a hole in the parietal bone."],"recent_major_changes":["Boxed Warning 10/2026 Indications and Usage, Unresectable or Metastatic Breast Cancer ( 1.1 ) 10/2026 Dosage and Administration ( 2.2 , 2.3 ) 10/2026 Warnings and Precautions ( 5.1 , 5.2 , 5.4 ) 10/2026"],"recent_major_changes_table":["<table cellpadding=\"0pt\" styleCode=\"Noautorules\" width=\"100%\"> <col width=\"92%\"/> <col width=\"8%\"/> <tbody> <tr> <td valign=\"top\"> <paragraph>Boxed Warning</paragraph> </td> <td align=\"right\" valign=\"top\"> <paragraph>10/2026</paragraph> </td> </tr> <tr> <td valign=\"top\"> <paragraph>Indications and Usage, Unresectable or Metastatic Breast Cancer (<linkHtml href=\"#ID_1e5967cb-ad86-4957-b951-7b569a289b3d\">1.1</linkHtml>)</paragraph> </td> <td align=\"right\" valign=\"top\"> <paragraph>10/2026</paragraph> </td> </tr> <tr> <td valign=\"top\"> <paragraph>Dosage and Administration (<linkHtml href=\"#ID_a279427e-f1ac-4ebb-810b-2d9ab77cc4b6\">2.2</linkHtml>, <linkHtml href=\"#ID_a4680616-9348-40f4-986a-8fd63413a59c\">2.3</linkHtml>)</paragraph> </td> <td align=\"right\" valign=\"top\"> <paragraph>10/2026</paragraph> </td> </tr> <tr> <td valign=\"top\"> <paragraph>Warnings and Precautions (<linkHtml href=\"#ID_15dc5fad-9ece-481b-8f94-079b3ce7ff10\">5.1</linkHtml>, <linkHtml href=\"#ID_48f2eb1d-b7d6-4a5b-8a39-bead01de0cbb\">5.2</linkHtml>, <linkHtml href=\"#ID_98BC3E32-EC3D-42CE-B21B-B338043EB502\">5.4</linkHtml>)</paragraph> </td> <td align=\"right\" valign=\"top\"> <paragraph>10/2026</paragraph> </td> </tr> </tbody> </table>"],"set_id":"f27eb1b9-b7fc-424e-988f-84dd7bb195a3","spl_medguide":["This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 10/2026 MEDICATION GUIDE TUKYSA ® (too-KYE-sah) (tucatinib) tablets Important: If your healthcare provider prescribes TUKYSA in combination with capecitabine or pertuzumab, also read the Patient Information that comes with capecitabine or pertuzumab. What is the most important information I should know about TUKYSA? TUKYSA can cause serious side effects, including: • Liver Problems. TUKYSA can cause severe liver problems that can lead to death, especially if you restart TUKYSA after previously stopping treatment due to liver problems. Your healthcare provider will do blood tests to check your liver function before starting treatment with TUKYSA, every 2 weeks for the first 2 months, and then every 3 weeks during treatment with TUKYSA, or as needed. Tell your healthcare provider right away if you get any signs and symptoms of liver problems including: o itching o yellowing of your skin or eyes o dark or brown urine (tea-colored) o pain in the upper right side of your stomach-area (abdomen) o feeling very tired o decreased appetite o bleeding or bruising more easily than normal • Diarrhea. TUKYSA can cause severe diarrhea that can lead to loss of too much body fluids (dehydration), low blood pressure, kidney problems, and death. Tell your healthcare provider right away if you have a change in your bowel movements or severe diarrhea. Your healthcare provider may prescribe medicines to treat your diarrhea during treatment with TUKYSA. See “What are the possible side effects of TUKYSA?” for more information about side effects. What is TUKYSA? TUKYSA is a prescription medicine used in adults: • in combination with the medicines trastuzumab and pertuzumab for maintenance treatment of a type of breast cancer called human epidermal growth factor receptor-2 (HER2)-positive breast cancer that has spread: o to nearby tissue or lymph nodes and cannot be removed by surgery (unresectable locally advanced) or o to other parts of the body (metastatic). • in combination with trastuzumab and capecitabine to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic), or cannot be removed by surgery, who have received 1 or more anti-HER2 metastatic breast cancer treatments. • in combination with the medicine trastuzumab to treat a type of colorectal cancer called RAS wild-type HER2-positive colorectal cancer that has spread to other parts of the body (metastatic), or cannot be removed by surgery, who have received treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and it did not work or is no longer working. Your healthcare provider will perform a test to make sure TUKYSA is right for you. It is not known if TUKYSA is safe and effective in children. Before taking TUKYSA, tell your healthcare provider about all of your medical conditions, including if you: • have liver problems. • are pregnant or plan to become pregnant. TUKYSA can harm your unborn baby. Females who are able to become pregnant: o Your healthcare provider will do a pregnancy test before you start treatment with TUKYSA. o Use effective birth control (contraception) during treatment with TUKYSA and for 1 week after the last dose of TUKYSA. Talk with your healthcare provider about forms of birth control that you can use during this time. o Your healthcare provider will tell you how long you should use birth control (contraception) after your treatment with trastuzumab, pertuzumab, or capecitabine. o Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TUKYSA. Males with female partner who are able to become pregnant: o Use effective birth control during treatment with TUKYSA and for 1 week after the last dose of TUKYSA. • are breastfeeding or plan to breastfeed. It is not known if TUKYSA passes into your breast milk. Do not breastfeed during treatment with TUKYSA and for 1 week after the last dose of TUKYSA. Your healthcare provider will tell you how long you should not breastfeed after your treatment with trastuzumab and pertuzumab. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TUKYSA may affect the way your other medicines work, and other medicines may affect the way TUKYSA works. Know the medicines you take. Keep a list of all the medicines you take and show it to your healthcare provider and pharmacist every time you get a new medicine. How should I take TUKYSA? • Take TUKYSA exactly as your healthcare provider tells you. • Follow your healthcare provider’s instruction for taking TUKYSA with the medicines trastuzumab, trastuzumab and capecitabine, or trastuzumab and pertuzumab. • Take TUKYSA 2 times a day, with or without a meal. • Take TUKYSA about 12 hours apart and at the same times every day. • Swallow TUKYSA tablets whole. Do not chew, crush, or split TUKYSA tablets before swallowing. Do not take TUKYSA tablets if they are broken, cracked, or damaged. • If you vomit or miss a dose of TUKYSA, take your next dose at your regular time. What are the possible side effects of TUKYSA? TUKYSA can cause serious side effects, including: • See “What is the most important information I should know about TUKYSA?” The most common side effects of TUKYSA in combination with trastuzumab and pertuzumab in adults with HER2-positive breast cancer include: • diarrhea • muscle and joint pain • liver problems • nausea • tiredness • rash • vomiting The most common side effects of TUKYSA in combination with trastuzumab and capecitabine in adults with HER2-positive breast cancer include: • diarrhea • rash, redness, pain, swelling or blisters on the palms of your hands or soles of your feet • nausea • liver problems • vomiting • mouth sores (stomatitis) • decreased appetite • low red blood cell counts (anemia) • rash The most common side effects of TUKYSA in combination with trastuzumab in adults with RAS wild-type HER2-positive colorectal cancer include: • diarrhea • tiredness • rash • nausea • stomach-area (abdomen) pain • infusion related reactions • fever Your healthcare provider may change your dose of TUKYSA, temporarily stop, or permanently stop treatment with TUKYSA if you have certain side effects. TUKYSA may cause fertility problems in males and females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility. These are not all of the possible side effects of TUKYSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store TUKYSA? • Store TUKYSA at room temperature between 68°F to 77°F (20ºC to 25ºC). • Keep TUKYSA in its original container. The TUKYSA bottle contains a desiccant packet to help keep your tablets dry (protect from moisture). Keep the desiccant in the bottle. • Tightly close the bottle of TUKYSA after you take your dose. • TUKYSA must be used within 3 months after opening the bottle. Throw away (discard) any unused tablets 3 months after opening the bottle. Keep TUKYSA and all medicines out of the reach of children. General information about the safe and effective use of TUKYSA. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TUKYSA for a condition for which it was not prescribed. Do not give TUKYSA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TUKYSA that is written for health professionals. What are the ingredients in TUKYSA? Active ingredient: tucatinib Inactive ingredients: Tablet core: copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose. Tablet coating: yellow film coat: polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, talc, and yellow iron oxide non-irradiated. This product’s labeling may have been updated. For the most recent prescribing information, please visit https://www.pfizer.com . Manufactured for: Seagen Inc., Bothell, WA 98021 TUKYSA is a registered trademark owned by Seagen Inc. ©2026 Seagen Inc. For more information, call 1-800-438-1985. LAB-1594-1.0"],"spl_medguide_table":["<table width=\"100%\"> <col width=\"2%\"/> <col width=\"49%\"/> <col width=\"48%\"/> <tfoot> <tr> <td align=\"left\" colspan=\"3\" valign=\"top\">This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 10/2026</td> </tr> </tfoot> <tbody> <tr> <td align=\"center\" colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">MEDICATION GUIDE</content> </paragraph> <paragraph> <content styleCode=\"bold\">TUKYSA<sup>&#xAE;</sup> (too-KYE-sah)</content> </paragraph> <paragraph> <content styleCode=\"bold\">(tucatinib)</content> </paragraph> <paragraph> <content styleCode=\"bold\">tablets</content> </paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Important:</content> If your healthcare provider prescribes TUKYSA in combination with capecitabine or pertuzumab, also read the Patient Information that comes with capecitabine or pertuzumab.</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Toprule \" valign=\"top\"> <paragraph ID=\"mostimportantinfo\"> <content styleCode=\"bold\">What is the most important information I should know about TUKYSA?</content> </paragraph> <paragraph> <content styleCode=\"bold\">TUKYSA can cause serious side effects, including:</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Liver Problems.</content> TUKYSA can cause severe liver problems that can lead to death, especially if you restart TUKYSA after previously stopping treatment due to liver problems. Your healthcare provider will do blood tests to check your liver function before starting treatment with TUKYSA, every 2 weeks for the first 2 months, and then every 3 weeks during treatment with TUKYSA, or as needed. Tell your healthcare provider right away if you get any signs and symptoms of liver problems including:</item> </list> </td> </tr> <tr> <td styleCode=\"Lrule \" valign=\"top\"/> <td valign=\"top\"> <list listType=\"unordered\"> <item> <caption>o</caption>itching</item> <item> <caption>o</caption>yellowing of your skin or eyes</item> <item> <caption>o</caption>dark or brown urine (tea-colored)</item> <item> <caption>o</caption>pain in the upper right side of your stomach-area (abdomen)</item> </list> </td> <td styleCode=\"Rrule \" valign=\"top\"> <list listType=\"unordered\"> <item> <caption>o</caption>feeling very tired</item> <item> <caption>o</caption>decreased appetite</item> <item> <caption>o</caption>bleeding or bruising more easily than normal</item> </list> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption> <content styleCode=\"bold\">Diarrhea.</content> TUKYSA can cause severe diarrhea that can lead to loss of too much body fluids (dehydration), low blood pressure, kidney problems, and death. Tell your healthcare provider right away if you have a change in your bowel movements or severe diarrhea. Your healthcare provider may prescribe medicines to treat your diarrhea during treatment with TUKYSA.</item> </list> <paragraph>See <content styleCode=\"bold\"> <linkHtml href=\"#whatarepossiblesideeffects\">&#x201C;What are the possible side effects of TUKYSA?&#x201D;</linkHtml> </content> for more information about side effects.</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">What is TUKYSA?</content> </paragraph> <paragraph>TUKYSA is a prescription medicine used in adults:</paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>in combination with the medicines trastuzumab and pertuzumab for maintenance treatment of a type of breast cancer called human epidermal growth factor receptor-2 (HER2)-positive breast cancer that has spread: <list listType=\"unordered\"> <item> <caption>o</caption>to nearby tissue or lymph nodes and cannot be removed by surgery (unresectable locally advanced) <content styleCode=\"bold\">or</content> </item> <item> <caption>o</caption>to other parts of the body (metastatic). </item> </list> </item> <item> <caption>&#x2022;</caption>in combination with trastuzumab and capecitabine to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic), or cannot be removed by surgery, who have received 1 or more anti-HER2 metastatic breast cancer treatments.</item> <item> <caption>&#x2022;</caption>in combination with the medicine trastuzumab to treat a type of colorectal cancer called RAS wild-type HER2-positive colorectal cancer that has spread to other parts of the body (metastatic), or cannot be removed by surgery, who have received treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and it did not work or is no longer working.</item> </list> <paragraph>Your healthcare provider will perform a test to make sure TUKYSA is right for you.</paragraph> <paragraph>It is not known if TUKYSA is safe and effective in children.</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Before taking TUKYSA, tell your healthcare provider about all of your medical conditions, including if you:</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>have liver problems.</item> <item> <caption>&#x2022;</caption>are pregnant or plan to become pregnant. TUKYSA can harm your unborn baby.  <content styleCode=\"bold\">Females who are able to become pregnant:</content> <list listType=\"unordered\"> <item> <caption>o</caption>Your healthcare provider will do a pregnancy test before you start treatment with TUKYSA.</item> <item> <caption>o</caption>Use effective birth control (contraception) during treatment with TUKYSA and for 1 week after the last dose of TUKYSA. Talk with your healthcare provider about forms of birth control that you can use during this time.</item> <item> <caption>o</caption>Your healthcare provider will tell you how long you should use birth control (contraception) after your treatment with trastuzumab, pertuzumab, or capecitabine. </item> <item> <caption>o</caption>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TUKYSA. </item> </list> </item> <item> <caption> </caption> <content styleCode=\"bold\">Males with female partner who are able to become pregnant:</content> <list listType=\"ordered\"> <item> <caption>o</caption>Use effective birth control during treatment with TUKYSA and for 1 week after the last dose of TUKYSA.</item> </list> </item> <item> <caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. It is not known if TUKYSA passes into your breast milk. <content styleCode=\"bold\">Do not</content> breastfeed during treatment with TUKYSA and for 1 week after the last dose of TUKYSA. Your healthcare provider will tell you how long you should not breastfeed after your treatment with trastuzumab and pertuzumab. </item> </list> <paragraph> <content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. TUKYSA may affect the way your other medicines work, and other medicines may affect the way TUKYSA works.</paragraph> <paragraph>Know the medicines you take. Keep a list of all the medicines you take and show it to your healthcare provider and pharmacist every time you get a new medicine. </paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">How should I take TUKYSA?</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>Take TUKYSA exactly as your healthcare provider tells you.</item> <item> <caption>&#x2022;</caption>Follow your healthcare provider&#x2019;s instruction for taking TUKYSA with the medicines trastuzumab, trastuzumab and capecitabine, or trastuzumab and pertuzumab.</item> <item> <caption>&#x2022;</caption>Take TUKYSA 2 times a day, with or without a meal.</item> <item> <caption>&#x2022;</caption>Take TUKYSA about 12 hours apart and at the same times every day.</item> <item> <caption>&#x2022;</caption>Swallow TUKYSA tablets whole. <content styleCode=\"bold\">Do not</content> chew, crush, or split TUKYSA tablets before swallowing. <content styleCode=\"bold\">Do not</content> take TUKYSA tablets if they are broken, cracked, or damaged.</item> <item> <caption>&#x2022;</caption>If you vomit or miss a dose of TUKYSA, take your next dose at your regular time. </item> </list> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Toprule \" valign=\"top\"> <paragraph ID=\"whatarepossiblesideeffects\"> <content styleCode=\"bold\">What are the possible side effects of TUKYSA?</content> </paragraph> <paragraph> <content styleCode=\"bold\">TUKYSA can cause serious side effects, including:</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>See <content styleCode=\"bold\"> <linkHtml href=\"#mostimportantinfo\">&#x201C;What is the most important information I should know about TUKYSA?&#x201D;</linkHtml> </content> </item> </list> <paragraph> <content styleCode=\"bold\">The most common side effects of TUKYSA in combination with trastuzumab and pertuzumab in adults with HER2-positive breast cancer include:</content> </paragraph> </td> </tr> <tr> <td colspan=\"2\" styleCode=\"Lrule \" valign=\"top\"> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>diarrhea</item> <item> <caption>&#x2022;</caption>muscle and joint pain</item> <item> <caption>&#x2022;</caption>liver problems</item> <item> <caption>&#x2022;</caption>nausea</item> </list> </td> <td styleCode=\"Rrule \" valign=\"top\"> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>tiredness</item> <item> <caption>&#x2022;</caption>rash</item> <item> <caption>&#x2022;</caption>vomiting</item> </list> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">The most common side effects of TUKYSA in combination with trastuzumab and capecitabine in adults with HER2-positive breast cancer include:</content> </paragraph> </td> </tr> <tr> <td colspan=\"2\" styleCode=\"Lrule \" valign=\"top\"> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>diarrhea</item> <item> <caption>&#x2022;</caption>rash, redness, pain, swelling or blisters on the palms of your hands or soles of your feet</item> <item> <caption>&#x2022;</caption>nausea</item> <item> <caption>&#x2022;</caption>liver problems</item> </list> </td> <td styleCode=\"Rrule \" valign=\"top\"> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>vomiting</item> <item> <caption>&#x2022;</caption>mouth sores (stomatitis)</item> <item> <caption>&#x2022;</caption>decreased appetite</item> <item> <caption>&#x2022;</caption>low red blood cell counts (anemia)</item> <item> <caption>&#x2022;</caption>rash</item> </list> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">The most common side effects of TUKYSA in combination with trastuzumab in adults with RAS wild-type HER2-positive colorectal cancer include:</content> </paragraph> </td> </tr> <tr> <td colspan=\"2\" styleCode=\"Lrule Botrule \" valign=\"top\"> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>diarrhea</item> <item> <caption>&#x2022;</caption>tiredness</item> <item> <caption>&#x2022;</caption>rash</item> <item> <caption>&#x2022;</caption>nausea</item> </list> </td> <td styleCode=\"Rrule Botrule \" valign=\"top\"> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>stomach-area (abdomen) pain</item> <item> <caption>&#x2022;</caption>infusion related reactions</item> <item> <caption>&#x2022;</caption>fever</item> </list> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">Your healthcare provider may change your dose of TUKYSA, temporarily stop, or permanently stop treatment with TUKYSA if you have certain side effects.</content> </paragraph> <paragraph>TUKYSA may cause fertility problems in males and females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.</paragraph> <paragraph>These are not all of the possible side effects of TUKYSA. </paragraph> <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">How should I store TUKYSA?</content> </paragraph> <list listType=\"unordered\"> <item> <caption>&#x2022;</caption>Store TUKYSA at room temperature between 68&#xB0;F to 77&#xB0;F (20&#xBA;C to 25&#xBA;C).</item> <item> <caption>&#x2022;</caption>Keep TUKYSA in its original container. The TUKYSA bottle contains a desiccant packet to help keep your tablets dry (protect from moisture). Keep the desiccant in the bottle.</item> <item> <caption>&#x2022;</caption>Tightly close the bottle of TUKYSA after you take your dose.</item> <item> <caption>&#x2022;</caption>TUKYSA must be used within 3 months after opening the bottle. Throw away (discard) any unused tablets 3 months after opening the bottle.</item> </list> <paragraph> <content styleCode=\"bold\">Keep TUKYSA and all medicines out of the reach of children.</content> </paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">General information about the safe and effective use of TUKYSA.</content> </paragraph> <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TUKYSA for a condition for which it was not prescribed. Do not give TUKYSA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TUKYSA that is written for health professionals.</paragraph> </td> </tr> <tr> <td colspan=\"3\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"> <paragraph> <content styleCode=\"bold\">What are the ingredients in TUKYSA?</content> </paragraph> <paragraph> <content styleCode=\"bold\">Active ingredient:</content> tucatinib</paragraph> <paragraph> <content styleCode=\"bold\">Inactive ingredients:</content> </paragraph> <paragraph>Tablet core: copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose.</paragraph> <paragraph>Tablet coating: yellow film coat: polyvinyl alcohol, titanium dioxide, macrogol/polyethylene glycol, talc, and yellow iron oxide non-irradiated.   This product&#x2019;s labeling may have been updated. For the most recent prescribing information, please visit <linkHtml href=\"https://www.pfizer.com/\">https://www.pfizer.com</linkHtml>.   Manufactured for: Seagen Inc., Bothell, WA 98021 TUKYSA is a registered trademark owned by Seagen Inc. &#xA9;2026 Seagen Inc. For more information, call 1-800-438-1985.  LAB-1594-1.0</paragraph> </td> </tr> </tbody> </table>"],"spl_product_data_elements":["TUKYSA tucatinib Tucatinib Tucatinib Copovidone K25-31 Crospovidone (120 .Mu.M) Sodium Chloride Potassium Chloride Sodium Bicarbonate Silicon Dioxide Magnesium Stearate Microcrystalline Cellulose 102 Polyvinyl Alcohol, Unspecified Titanium Dioxide Polyethylene Glycol, Unspecified Talc Ferric Oxide Yellow TUC;50 TUKYSA tucatinib Tucatinib Tucatinib Copovidone K25-31 Crospovidone (120 .Mu.M) Sodium Chloride Potassium Chloride Sodium Bicarbonate Silicon Dioxide Magnesium Stearate Microcrystalline Cellulose 102 Polyvinyl Alcohol, Unspecified Titanium Dioxide Polyethylene Glycol, Unspecified Talc Ferric Oxide Yellow TUC;150"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary TUKYSA is used in combination with other agents. Refer to the Prescribing Information of combination agents for pregnancy information. Based on findings in animals and its mechanism of action, TUKYSA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available human data on TUKYSA use in pregnant women to inform a drug-associated risk. In animal reproduction studies, administration of tucatinib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal mortality, reduced fetal weight and fetal abnormalities at maternal exposures ≥1.3 times the human exposure (AUC) at the recommended dose (see Data ) . Advise pregnant women and females of reproductive potential of the potential risk to the fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Data Animal Data In pilot embryo-fetal development studies, pregnant rats and rabbits received oral doses of tucatinib up to 150 mg/kg/day during the period of organogenesis. In rats, oral administration of tucatinib resulted in maternal toxicity (body weight loss, reduced body weight gain, low food consumption) at doses ≥90 mg/kg/day. Fetal effects included reduced number of live fetuses, decreased fetal weight, and fetal abnormalities (increase in skeletal variations, incomplete ossification) at ≥90 mg/kg/day (approximately 3.5 times the human exposure at the recommended dose based on AUC). In rabbits, oral administration of tucatinib resulted in increased resorptions, decreased percentages of live fetuses, and skeletal, visceral, and external malformations in fetuses at doses ≥90 mg/kg/day (1.3 times the human exposure at the recommended dose based on AUC). Fetal abnormalities included domed head, brain dilation, incomplete ossification of frontal and parietal bones, and a hole in the parietal bone. 8.2 Lactation Risk Summary TUKYSA is used in combination with other agents. Refer to the Prescribing Information of combination agents for lactation information. When TUKYSA is used in combination, advise patients not to breastfeed during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products. There are no data on the presence of tucatinib or its metabolites in human or animal milk or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with TUKYSA and for 1 week after the last dose. 8.3 Females and Males of Reproductive Potential TUKYSA can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . TUKYSA is used in combination with other agents. Refer to the Prescribing Information of combination agents for contraception and infertility information. When TUKYSA is used in combination, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products. Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating treatment with TUKYSA. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose. Males Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose. Infertility Based on findings from animal studies, TUKYSA may impair male and female fertility [see Nonclinical Toxicology (13.1) ] . 8.4 Pediatric Use The safety and effectiveness of TUKYSA in pediatric patients have not been established. 8.5 Geriatric Use In HER2CLIMB-05, 51 patients who received TUKYSA were ≥65 years of age of whom 12 patients were ≥75 years of age. The incidence of ≥ Grade 3 adverse reactions was 57% in patients ≥65 years of age compared to 40% in patients <65 years of age. There were no overall differences in the effectiveness of TUKYSA in patients ≥65 years of age compared to younger patients. There were too few patients ≥75 years of age to assess differences in effectiveness or safety. In HER2CLIMB, 82 patients who received TUKYSA were ≥65 years of age, of whom 8 patients were ≥75 years of age. The incidence of serious adverse reactions in those receiving TUKYSA was 34% in patients ≥65 years of age compared to 24% in patients <65 years of age. The most frequent serious adverse reactions in patients ≥65 years of age who received TUKYSA were diarrhea (9%), vomiting (6%), and nausea (5%). There were no observed overall differences in the effectiveness of TUKYSA in patients ≥65 years of age compared to younger patients. There were too few patients ≥75 years of age to assess differences in effectiveness or safety. In MOUNTAINEER, 12 patients were ≥65 years of age. There were too few patients ≥65 years of age to assess differences in effectiveness or safety. 8.6 Renal Impairment The use of TUKYSA in combination with capecitabine and trastuzumab is not recommended in patients with severe renal impairment (creatinine clearance [CLcr]: <30 mL/min estimated by Cockcroft-Gault Equation), because capecitabine is contraindicated in patients with severe renal impairment. Refer to the Prescribing Information of capecitabine for additional information in severe renal impairment. No dose adjustment is recommended for patients with mild or moderate renal impairment (CLcr: 30 to 89 mL/min). 8.7 Hepatic Impairment Tucatinib exposure is increased in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of TUKYSA for patients with severe (Child‑Pugh C) hepatic impairment [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . No dose adjustment for TUKYSA is required for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment."],"version":"10","warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Diarrhea : TUKYSA can cause severe diarrhea, including dehydration, hypotension, acute kidney injury, and death. Administer antidiarrheal treatment as clinically indicated. Interrupt dose, reduce dose, or permanently discontinue TUKYSA based on severity. ( 2.3 , 5.2 ) • Embryo-Fetal Toxicity : TUKYSA can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.3 , 8.1 , 8.3 ) Refer to the Prescribing Information of combination agents for pregnancy and contraception information. • Increased Serum Creatinine Without Affecting Renal Function : Increases in serum creatinine can occur. Use alternative measures that are not based on serum creatinine to assess renal function. ( 5.4 ) 5.1 Hepatotoxicity TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge [see Adverse Reactions (6.1) ] . Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 2 weeks for the first 2 months, then every 3 weeks during treatment, and as clinically indicated. For patients who experience AST/ALT >3 × ULN and bilirubin > ULN to ≤2 × ULN, repeat testing within 48-72 hours. For patients who experience AST/ALT >5 × ULN, withhold TUKYSA and repeat testing within 48-72 hours to determine if worsening. Based on the severity of hepatotoxicity, reduce dose or permanently discontinue TUKYSA [see Dosage and Administration (2.3) ] . Institute weekly liver function monitoring if TUKYSA is resumed after resolution to Grade ≤1. TUKYSA with trastuzumab and pertuzumab In HER2CLIMB-05, 18% of patients who received TUKYSA had an ALT increase >5 × ULN, 10% had an AST increase >5 × ULN, and 1.2% had a bilirubin increase >3 × ULN (Grade ≥3). There were five confirmed Hy’s Law cases, including a fatal case. All occurred following rechallenge with TUKYSA. Hepatotoxicity led to dose reduction of TUKYSA in 16% of patients and discontinuation of TUKYSA in 8% of patients. TUKYSA with trastuzumab and capecitabine In HER2CLIMB, 8% of patients who received TUKYSA had an ALT increase >5 × ULN, 6% had an AST increase >5 × ULN, and 1.5% had a bilirubin increase >3 × ULN (Grade ≥3). Hepatotoxicity led to dose reduction of TUKYSA in 8% of patients and discontinuation of TUKYSA in 1.5% of patients. TUKYSA with trastuzumab In MOUNTAINEER, 6% of patients had a bilirubin increase >3 × ULN (Grade ≥3), 6% had an AST increase >5 × ULN, and 4.7% had an ALT increase >5 × ULN. Hepatotoxicity led to dose reduction of TUKYSA in 3.5% of patients and discontinuation of TUKYSA in 2.3% of patients. 5.2 Diarrhea TUKYSA can cause severe diarrhea, including dehydration, hypotension, acute kidney injury, and death [see Adverse Reactions (6.1) ] . If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Based on the diarrhea severity, interrupt dose, reduce dose, or permanently discontinue TUKYSA [see Dosage and Administration (2.3) ] . TUKYSA with trastuzumab and pertuzumab In HER2CLIMB-05, 73% of patients who received TUKYSA experienced diarrhea, including 6% with Grade 3 events. The median time to onset of the first episode of diarrhea was 11 days and the median time to resolution was 2 days. Diarrhea led to dose reductions of TUKYSA in 6% of patients and discontinuation of TUKYSA in 1.5% of patients. Prophylactic use of antidiarrheal treatment was not required in HER2CLIMB-05. TUKYSA with trastuzumab and capecitabine In HER2CLIMB, 81% of patients who received TUKYSA experienced diarrhea, including 0.5% with Grade 4 diarrhea and 12% with Grade 3 diarrhea. Both patients who developed Grade 4 diarrhea subsequently died, with diarrhea as a contributor to death. The median time to onset of the first episode of diarrhea was 12 days and the median time to resolution was 8 days. Diarrhea led to dose reductions of TUKYSA in 6% of patients and discontinuation of TUKYSA in 1% of patients. Prophylactic use of antidiarrheal treatment was not required in HER2CLIMB. TUKYSA with trastuzumab In MOUNTAINEER, diarrhea occurred in 64% of patients, including Grade 3 (3.5%), Grade 2 (10%), and Grade 1 (50%). 5.3 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, TUKYSA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of tucatinib to pregnant rats and rabbits during organogenesis caused embryo-fetal mortality, reduced fetal weight and fetal abnormalities at maternal exposures ≥1.3 times the human exposure (AUC) at the recommended dose. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TUKYSA and for 1 week after the last dose [see Use in Specific Populations (8.1 , 8.3 )] . TUKYSA is used in combination with other agents. Refer to the Prescribing Information of combination agents for pregnancy and contraception information. 5.4 Increased Serum Creatinine Without Affecting Renal Function TUKYSA can increase serum creatinine. Across three clinical trials in 816 patients (HER2CLIMB-05, HER2CLIMB, and MOUNTAINEER), the mean increase in serum creatinine was 29%-32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible upon treatment completion. These increases were not associated with changes in glomerular function [see Adverse Reactions (6.1) ] . These increases in serum creatinine may be due to inhibition of renal tubular transport of creatinine. During TUKYSA treatment, use alternative measures that are not based on serum creatinine to assess renal function [see Clinical Pharmacology (12.3) ] ."]}